Document:

EX-10.16

 Exhibit 10.16 

 

	[***]	 Certain information in this document has been omitted from this exhibit because it is both (i) not
material and (ii) would be competitively harmful if publicly disclosed. 

 PATENT LICENSE AGREEMENT
— EXCLUSIVE 
 This Cover Page identifies the Parties to this Agreement: 

The Frederick National Laboratory for Cancer Research, operated by Leidos Biomedical Research, Inc. under 

sponsorship from the National Cancer Institute (NCI) 

(hereinafter referred to as “Leidos Biomedical”) 

  and 
 THERAS, INC.

 hereinafter referred to as the “Licensee” 

having offices at 421 Kipling St, Palo Alto, Ca 94301, 

created and operating under the laws of Delaware. 

Tax ID No.:                     

  
 CONFIDENTIAL 

Patent License Agreement – Exclusive 
 Page 1 of 28
[Final] [Theras] [Friday, December 14, 2018] 
 1 
 [Page 1 of
28] ● 

 For the LBR internal use only: 

License Number: [***] 
 Serial
Number(s) of Licensed Patent(s) or Patent Application(s): 
 Cooperative Research and Development Agreement (CRADA) Number (if a subject
invention): 
 Additional Remarks: 

Public Benefit(s): 
 This Patent License
Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory),
Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 2 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 2 of 28] ●

 The Leidos Biomedical and the Licensee agree as follows: 

 

	1.	 BACKGROUND 

  

	 	1.1	 In the course of conducting research under a Cooperative Research and Development Agreement (CRADA) entered
into with Licensee, the Leidos Biomedical investigators made inventions that may have commercial applicability and are of interest to Licensee. 

  

	 	1.2	 By assignment of rights from Leidos Biomedical employees and other inventors, Leidos
Biomedical owns (either solely or jointly) certain intellectual property rights claimed in any United States or foreign patent applications or patents corresponding to the assigned inventions. Leidos Biomedical also owns any
tangible embodiments of these inventions actually reduced to practice. The Government has certain rights in inventions. 

  

	 	1.3	 Leidos Biomedical desires to transfer these inventions to the private sector through commercialization licenses
to facilitate the commercial development of products and processes for public use and benefit. 

  

	 	1.4	 The Licensee desires to acquire commercialization rights to certain of these inventions in order to
develop processes, methods, or marketable products for public use and benefit. 

  

	2.	 DEFINITIONS 

  

	 	2.1	 “Affiliate(s)” means a corporation or other business entity, which directly or
indirectly is controlled by or controls, or is under common control with the Licensee. For this purpose, the term “control” shall mean ownership of more than fifty percent (50%) of the voting stock or other ownership interest of the
corporation or other business entity, or the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the corporation or other business entity. 

 

	 	2.2	 “Benchmarks” mean the performance milestones that are set forth in Appendix D.

  

	 	2.3	 “Combination Product” means a product that in a single formulation or in a single
package or otherwise sold for a single price contains both a compound that is a Licensed Product, as defined herein, and one or more Combination Product Component(s), provided that (i) such Combination Product Component and such Licensed
Product are capable of being sold (but may not be actually sold) either separately from such combined product, with or without other therapeutic products, by the Licensee or any Affiliate, or Sublicensee or the patent holder of the Combination
Product Component and (ii) the market price of such combined product is higher than the market price for such Licensed Product (or what should have been if such Licensed Product is not Sold separately) as a result of such combined
product containing or using such Combination Product Component. 

  

	 	2.4	 “Combination Product Component” means a therapeutically active compound, a
proprietary device (if applicable), or a proprietary formulation that is not a Licensed Product but is covered by the intellectual property rights owned or controlled by the Licensee, without which compound or device the Licensed Product would
deliver less therapeutic effect (but no an excipient, coating, capsule or other non-proprietary delivery system or formulation) that is not a Licensed Product but that is included in a Combination Product. For the sake of clarity, a drug delivery
device that is 

  
 CONFIDENTIAL 

Patent License Agreement – Exclusive 
 Page 3 of 28
[Final] [Theras] [Friday, December 14, 2018] 
 1 
 [Page 3 of
28] ● 

	 	
used for the delivery of drug products in general and is readily available for hospital, clinic and/or in-home use, such as a syringe, intravenous inject ports and the like, would not be deemed a
proprietary device and therefore, would not be deemed a Combination Product Component. In addition, a proprietary formulation or proprietary device shall only include formulation or devices that are developed by or on behalf of Licensee or in-licensed, purchased or otherwise procured by the Licensee, its Affiliates and/or sublicensees from a third party for value. 

  

	 	2.5	 “Commercial Development Plan” means the written commercialization plan attached
as Appendix E. 

  

	 	2.6	 “CRADA” means a Cooperative Research and Development Agreement. 

 

	 	2.7	 “FDA” means the Food and Drug Administration. 

 

	 	2.8	 “First Commercial Sale” means the initial transfer by or on behalf of the
Licensee or its sublicensees of the Licensed Products or the initial practice of a Licensed Process by or on behalf of the Licensee or its sublicensees in exchange for cash or some equivalent to which value
can be assigned for the purpose of determining Net Sales. 

  

	 	2.9	 “Government” means the Government of the United States of America. 

 

	 	2.10	 “Licensed Fields of Use” means the fields of use identified in Appendix
B. 

  

	 	2.11	 “Licensed Patent Rights” shall mean: 

 

	 	(a)	 Patent applications (including provisional patent applications and PCT patent applications) or patents listed
in Appendix A, further provisional or nonprovisional applications filed within the Paris convention year of the patent applications listed in Appendix A and with claims to additional compounds or sub-genera that fall within the scope of the genus
described in the provisional applications listed and/or claiming priority benefit of the provisional applications in Appendix A that are, as of the effective date of this agreement, still within their Paris convention year (the “Paris
Convention Year Additional Claims”), all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of these patents;

  

	 	(b)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in 2.11(a): 

  

	 	(i)	 continuations-in-part of 2.11(a); 

 

	 	(ii)	 all divisions and continuations of these continuations-in-part; 

 

	 	(iii)	 all patents issuing from these continuations-in-part, divisions, and continuations; 

 

	 	(iv)	 priority patent application(s) of 2.11(a); and 

 

	 	(v)	 any reissues, reexaminations, and extensions of these patents; 

  
 CONFIDENTIAL 

Patent License Agreement – Exclusive 
 Page 4 of 28
[Final] [Theras] [Friday, December 14, 2018] 
 1 
 [Page 4 of
28] ● 

	 	(c)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in 2.11(a): all counterpart foreign and U.S. patent applications and patents to 2.11(a) and 2.11(b), including those listed in Appendix A; and 

  

	 	(d)	 Licensed Patent Rights shall not include 2.11(b) or 2.11(c) to the extent that they
contain one or more claims directed to new matter which is not the subject matter disclosed in 2119(a), except for the Paris Convention Year Additional Claims. 

 

	 	2.12	 “Licensed Processes” means processes which, in the course of being practiced, would be
within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction

  

	 	2.13	 “Licensed Product(s)” means tangible materials which, in the course of
manufacture, use, sale, or importation, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent
jurisdiction. 

  

	 	2.14	 “Licensed Territory” means the geographical area identified in Appendix B.

  

	 	2.15	 “Net Sales” means the total gross receipts for Sales of Licensed Products for
commercial use or provision of Licensed Processes as services for a fee by or on behalf of the Licensee or its sublicensees, less [***]. For the sake of clarity, Net Sales shall not include the [***]. 

 

	 	2.16	 “Practical Application” means to manufacture in the case of a composition or product,
to practice in the case of a process or method, or to operate in the case of a machine or system; and in each case, under these conditions as to establish that the invention is being utilized and that its benefits are to the extent permitted by law
or Government regulations available to the public on reasonable terms. 

  

	 	2.17	 “Sale” means the act of selling, leasing or otherwise transferring, providing or furnishing
for use for any consideration. 

  

	3.	 GRANT OF RIGHTS 

 

	 	3.1	 Leidos Biomedical hereby grants and the Licensee accepts, subject to the terms and
conditions of this Agreement, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to
import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Process(es) in the Licensed Fields of Use. To the
extent any Licensed Patents Rights is jointly owned by Leidos Biomedical and another entity (including Licensee), such exclusive license shall encompass only Leidos Biomedical’s interest in such jointly owned Licensed Patent Rights.

  

	 	3.2	 This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent
applications or patents of the Leidos Biomedical other than the Licensed Patent Rights regardless of whether these patents are dominant or subordinate to the Licensed Patent Rights. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 5 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 5 of 28] ●

	 	3.3	 Notwithstanding the foregoing, the Parties acknowledge that, the inventions claimed in the Licensed Patent
Rights are results of an ongoing research collaboration between Leidos Biomedical and Licensee, and Licensee has an option to any inventions resulting from such research collaboration. To that end, if and when Licensee exercises any such option, the
Parties shall execute an amendment to this Agreement to include such optioned inventions as part of the license hereunder with additional consideration to be negotiated by the Parties that would include [***] without changing the rates and
percentages for earned royalties and sublicensing royalties under this Agreement. 

  

	4.	 SUBLICENSING 

  

	 	4.1	 The Licensee shall have the right to grant sublicenses in multiple tiers to its Affiliates and third
party sublicensees (in the event of third party sublicensees, by entering into sublicensing agreements under the Licensed Patent Rights), and all such sublicenses are consistent with the terms and conditions of this Agreement.
For the purposes of this Agreement, a sublicensee shall include any person or entity (including any Affiliate) to which any of the license rights granted to the Licensee hereunder are granted a sublicense or an option to a sublicense,
but not including any subcontractors or vendors provided that Licensee is responsible for performance of such subcontractors (or vendors) in compliance with this Agreement and that such subcontractors or vendors do not provide any cash or
in-kind consideration to Licensee in exchange for Licensed Patent Rights. 

  

	 	4.2	 The Licensee agrees that any sublicenses granted by it shall provide that the obligations to
Leidos Biomedical of Paragraphs 5.1-5.4, 8.1, 10.1, 10.2, 12.5, and 13.8-13.10 of this Agreement shall be binding upon the sublicensee as if it were a party to the applicable provisions of this Agreement. The
Licensee further agrees to attach copies of these Paragraphs to all sublicense agreements. 

  

	 	4.3	 Any sublicenses granted by the Licensee shall provide for the termination of the sublicense, or the
conversion to a license directly between the sublicensees and Leidos Biomedical, at the option of the sublicensee, upon termination of this Agreement under Article 13. This conversion is subject to Leidos
Biomedical approval and contingent upon acceptance by the sublicensee of the remaining provisions of this Agreement. 

  

	 	4.4	 The Licensee agrees to forward to Leidos Biomedical a complete copy of each fully executed sublicense agreement
postmarked within thirty (30) days of the execution of the agreement, provided that Licensee may redact portions of such sublicense agreement that is pertinent to technology other than the Licensed Patent Rights. Leidos Biomedical agrees to
maintain each sublicense agreement in confidence. 

  

	5.	 STATUTORY REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS 

 

	 	5.1	 (a) Licensee agrees and Leidos Biomedical reserves on behalf of itself and the Government an
irrevocable, nonexclusive, nontransferable, royalty-free license for the practice of all inventions licensed under the Licensed Patent Rights throughout the world by or on behalf of the Government and on behalf of any
foreign government or international organization pursuant to any existing or future treaty or agreement to which the Government is a signatory. Upon request, prior to the First Commercial Sale, the Licensee agrees
to provide Leidos Biomedical with reasonable quantities of the Licensed Products or materials made through the Licensed Processes for Leidos Biomedical’s internal research use; and 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 6 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 6 of 28] ●

	 	(b)	 in the event that the Licensed Patent Rights are Subject inventions made under
CRADA, the Licensee grants to the Government, pursuant to 15 U.S.C. §3710a(c)(1)(A), a nonexclusive, nontransferable, irrevocable, paid-up license to practice the Licensed Patent Rights or have
the Licensed Patent Rights practiced throughout the world by or on behalf of the Government. In the exercise of this license, the Government shall not publicly disclose trade secrets or commercial or financial
information that is privileged or confidential within the meaning of 5 U.S.C. §552(b)(4) or which would be considered as such if it had been obtained from a non-Federal party. Prior to the First Commercial Sale, the
Licensee agrees to provide Leidos Biomedical with reasonable quantities of the Licensed Products or materials made through the Licensed Processes for Leidos Biomedical’s internal research use.

  

	 	5.2	 The Licensee agrees that products used or sold in the United States embodying the Licensed
Products or produced through use of the Licensed Processes shall be manufactured substantially in the United States, unless a written waiver is obtained in advance from the Leidos Biomedical. 

 

	 	5.3	 In exceptional circumstances, and in the event that the Licensed Patent Rights are Subject
Inventions made under a CRADA, Leidos Biomedical, as a national laboratory and under the auspices and direction of the Government, pursuant to and to the extent required by 15 U.S.C. §3710a(b)(1)(B), retains
the right to require the Licensee to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use the Licensed Patent Rights in the Licensed Field of Use
on terms that are reasonable under the circumstances, or if the Licensee fails to grant this license, the Government retains the right to grant the license itself. The exercise of these rights by the Government shall only be in
exceptional circumstances and only if the Government determines: 

  

	 	(i)	 the action is necessary to meet health or safety needs that are not reasonably satisfied by the
Licensee; 

  

	 	(ii)	 the action is necessary to meet requirements for public use specified by Federal regulations, and these
requirements are not reasonably satisfied by the Licensee; or 

  

	 	(iii)	 the Licensee has failed to comply with an agreement containing provisions described in 15 U.S.C.
§37l0a(c)(4)(B). 

  

	6.	 ROYALTIES AND REIMBURSEMENT 

 

	 	6.1	 The Licensee agrees to pay Leidos Biomedical a noncreditable, nonrefundable license issue
royalty as set forth in Appendix C. 

  

	 	6.2	 The Licensee agrees to pay Leidos Biomedical a nonrefundable minimum annual royalty as set forth in
Appendix C. 

  

	 	6.3	 The Licensee agrees to pay Leidos Biomedical earned royalties as set forth in Appendix C.

  
 CONFIDENTIAL 

Patent License Agreement – Exclusive 
 Page 7 of 28
[Final] [Theras] [Friday, December 14, 2018] 
 1 
 [Page 7 of
28] ● 

	 	6.4	 The Licensee agrees to pay Leidos Biomedical benchmark royalties as set forth in Appendix C.

  

	 	6.5	 The Licensee agrees to pay Leidos Biomedical sublicensing royalties as set forth in Appendix C.

  

	 	6.6	 A patent or patent application licensed under this Agreement shall cease to fall within the
Licensed Patent Rights for the purpose of computing earned royalty payments in any given country on the earliest of the dates that: 

  

	 	(a)	 the application has been abandoned and not continued; 

 

	 	(b)	 the patent expires or irrevocably lapses, 

 

	 	(c)	 the patent has been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of
competent jurisdiction or administrative agency. 

 No multiple royalties shall be payable because any Licensed
Products or Licensed Processes are covered by more than one of the Licensed Patent Rights. 
  

	 	6.7	 On sales of the Licensed Products by the Licensee to sublicensees or on sales made in
other than an arm’s-length transaction, the value of the Net Sales attributed under this Article 6 to this transaction shall be that which would have been received in an arm’s-length transaction, based on sales of like
quantity and quality products on or about the time of this transaction. 

  

	 	6.8	 If applicable, in the event Leidos Biomedical is the Party responsible for the preparation, filing, prosecution
and maintenance of any patent applications and patents included within the Licensed Patent Rights, Licensee will reimburse Leidos Biomedical of the expenses associated with the preparation, filing, prosecution, and maintenance of such patent
applications and patents reasonably incurred and paid by Leidos Biomedical on or after the effective date of this Agreement. 

  

	 	6.9	 The Licensee may elect to surrender its rights in any country of the Licensed Territory
under any of the Licensed Patent Rights upon [***] written notice to Leidos Biomedical and owe no payment obligation for patent-related expenses paid in that country after [***] of the effective date of the written
notice. 

  

	7.	 PATENT FILING, PROSECUTION, AND MAINTENANCE 

 

	 	7.1	 Except as otherwise provided in this Article 7, as between Leidos and Licensee, Licensee will be
responsible for, and consult with, Leidos Biomedical in the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights. 

 

	 	7.2	 Licensee shall, on a regular basis, furnish copies of all patent filings under Licensed Patent Rights to Leidos
Biomedical. In this event, the Licensee shall select registered patent attorneys or patent agents to provide these services on behalf of the Licensee and Leidos Biomedical. Leidos Biomedical shall provide appropriate powers of attorney
and other documents necessary to undertake this action to the patent attorneys or patent agents providing these services. The Licensee and its attorneys or agents shall consult with Leidos Biomedical reasonably and as practicable in the
preparation, filing, prosecution and maintenance of patent applications and 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 8 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 8 of 28] ●

	 	
patents included within the Licensed Patent Rights and shall provide Leidos Biomedical with sufficient opportunity to comment on any patent filing or response to office action that the
Licensee intends to file or to cause to be filed with the relevant intellectual property or patent office. 

  

	 	7.3	 In the event Licensee notifies Leidos Biomedical in writing that it decides to discontinue the prosecution or
maintenance of certain Licensed Patent Rights, Leidos Biomedical may provide the Licensee with written notice that Leidos Biomedical wishes to assume control of the prosecution, and maintenance of such Licensed Patent
Rights. If Leidos Biomedical elects to assume these responsibilities, the Licensee agrees to cooperate fully with Leidos Biomedical, its attorneys, and agents in the preparation, filing, prosecution, and maintenance of the applicable
Licensed Patent Rights and to provide Leidos Biomedical with complete copies of any and all documents or other materials necessary to undertake such responsibilities. The Licensee shall be responsible for all costs of
Licensee and Licensee’s patent attorneys associated with transferring patent prosecution responsibilities to an attorney or agent of Leidos Biomedical’s choice. 

 

	 	7.4	 Each party shall promptly inform the other as to all matters that come to its attention that may materially
affect the preparation, filing, prosecution, or maintenance of the Licensed Patent Rights and, reasonably and as practicable, permit each other to provide comments and suggestions with respect to the preparation, filing,
prosecution, and maintenance of the Licensed Patent Rights, which comments and suggestions shall be considered by the other party. 

  

	8.	 RECORD KEEPING 

 

	 	8.1	 The Licensee agrees to keep accurate and correct records of the Licensed Products made,
used, sold, or imported and the Licensed Processes practiced under this Agreement appropriate to determine the amount of royalties due to Leidos Biomedical. These records shall be retained for at least [***] years following a
given reporting period and shall be available during normal business hours for inspection with at least [***] prior written notice, at the expense of Leidos Biomedical, by an accountant or other designated auditor selected by Leidos Biomedical for
the sole purpose of verifying reports and royalty payments hereunder, provided that such inspection shall be no more frequent than once per calendar year. The accountant or auditor shall only disclose to Leidos Biomedical information relating to the
accuracy of reports and royalty payments made under this Agreement, and all information learned by such accountant or auditor, and all information disclosed to Leidos Biomedical, shall be deemed Confidential Information of Licensee. If an
inspection shows an underreporting or underpayment in excess of [***] percent ([***]%) for any twelve (12) month period, then the Licensee shall reimburse Leidos Biomedical for the cost of the inspection at the time the
Licensee pays the unreported royalties, including any additional royalties as required by Paragraph 9.8. All undisputed unreported royalty payments required under this Paragraph shall be due within [***] days of the date Leidos Biomedical
provides to the Licensee notice of the payment due. 

  

	9.	 REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS, 

 

	 	9.1	 Prior to signing this Agreement, the Licensee has provided Leidos Biomedical with the
Commercial Development Plan in Appendix E, under which the Licensee intends to bring the subject matter of the Licensed Patent Rights to the point of Practical Application. This
Commercial Development Plan is hereby incorporated by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 9 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 9 of 28] ●

	 	9.2	 The Licensee shall provide written annual reports on its product development progress or efforts to
commercialize under the Commercial Development Plan for the Licensed Fields of Use within [***] after December 31 of each calendar year. These progress reports shall be in summary form and
include, but not be limited to: progress on research and development, status of applications for regulatory approvals, manufacture and status of sublicensing, marketing, importing, and sales during the preceding calendar year, as well as, plans for
the present calendar year. Leidos Biomedical also encourages these reports to include information on any of the Licensee’s public service activities that relate to the Licensed Patent Rights. If reported progress differs from that
projected in the Commercial Development Plan and Benchmark, the Licensee shall explain the reasons for these differences. 

  

	 	9.3	 In the annual report, the Licensee may propose amendments to the Commercial Development
Plan, acceptance of which by Leidos Biomedical may not be denied unreasonably. The Licensee may amend the Benchmarks at any time upon written approval by Leidos Biomedical, which may not be unreasonably withheld. Leidos
Biomedical shall not withhold approval of any request of the Licensee to extend the time periods of this schedule if the request is supported by a reasonable showing by the Licensee of diligence in its performance under the
Commercial Development Plan and toward bringing the Licensed Products to the point of Practical Application as defined in 37 C.F.R. §404.3(d), or if the modification results from delays
outside Licensee’s reasonable control, such as for safety, efficacy and regulatory issues. The Licensee shall amend the Commercial Development Plan and Benchmarks at the request of Leidos Biomedical to address any
Licensed Fields of Use not specifically addressed in the plan originally submitted. 

  

	 	9.4	 The Licensee shall report to Leidos Biomedical the dates for achieving Benchmarks specified in
Appendix D and the First Commercial Sale in each country in the Licensed Territory within [***] of such occurrences. 

 

	 	9.5	 The Licensee shall submit to Leidos Biomedical, within [***] days after each calendar half-year ending
June 30 and December 31, a royalty report, as described in the example in Appendix F, setting forth tor the preceding half-year period the amount of the Licensed Product* sold or Licensed Processes
practiced by or on behalf of the Licensee in each country within the Licensed Territory, the Net Sales, and the amount of royalty accordingly due. With each royalty report, the Licensee skill submit payment
of earned royalties due. If no earned royalties are due to Leidos Biomedical for any reporting period, the written report shall so state. The royalty report shall be certified as correct by an authorized officer of the Licensee and shall
include a detailed listing of all deductions made under Paragraph 2.13 to determine Net Sales made under Article 6 to determine royalties due. The royalty report shall also identify the site of manufacture for the Licensed
Product(s) sold in the United States. 

  

	 	9.6	 The Licensee agrees to incorporate information received by Licensee regarding the Sales by its
sublicensees during the preceding half-year period to the extent pertinent to a royalty accounting to Leidos Biomedical by the Licensee for activities under the sublicense. 

 

	 	9.7	 Royalties due under Article 6 shall be paid in U.S. dollars and payment options are listed in Appendix G. For
conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York foreign exchange rate quoted in The Wall Street Journal on the day that the payment is due. Any loss of exchange, value, taxes, or other expenses
incurred in the transfer or conversion to U.S. dollars shall be paid entirely by the Licensee. The royalty report required by Paragraph 9.4 shall be mailed to Leidos Biomedical at its address for Agreement Notices indicated on the
Signature Page. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 10 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 10 of 28] ●

	 	9.8	 The Licensee shall be solely responsible for determining if any tax on royalty income is owed outside
the United States and shall pay the tax and be responsible for all filings with appropriate agencies of foreign governments. Leidos Biomedical shall be solely responsible for income tax imposed upon Leidos Biomedical as a result of payments it
receives under this Agreement. 

  

	 	9.9	 Additional royalties may be assessed by Leidos Biomedical on any payment that is more than [***] overdue at the
rate of [***] percent ([***]%) per [***]. This [***] percent ([***]%) per [***] rate may be applied retroactively from the original due date until the date of receipt by the Leidos Biomedical of the overdue payment and
additional royalties. The payment of any additional royalties shall not prevent Leidos Biomedical from exercising any other rights it may have as a consequence of the lateness of any payment. 

 

	 	9.10	 All plans and reports required by this Article 9 shall, to the extent permitted by law, be treated by Leidos
Biomedical as commercial and financial information obtained from a person and as privileged and confidential, and any proposed disclosure of these records by Leidos Biomedical under the Freedom of Information Act (FOIA), 5 U.S.C. §552
shall be subject to the predisclosure notification requirements of 45 C.F.R. §5.65(d), 

  

	10.	 PERFORMANCE 

  

	 	10.1	 The Licensee shall use its reasonable commercial efforts to bring the Licensed Products
and the Licensed Processes to Practical Application. The efforts of a sublicensee shall be considered the efforts of the Licensee. 

 

	 	10.2	 Upon the First Commercial Sale, until the expiration or termination of this
Agreement, the Licensee shall use Its reasonable commercial efforts to make the Licensed Products and the Licensed Processes reasonably accessible to the United States public. 

 

	 	10.3	 The Licensee agrees, after its First Commercial Sale, to make commercially reasonable
quantities of the Licensed Products or materials produced through the use of the Licensed Processes available to patient assistance programs. 

 

	 	10.4	 The Licensee agrees, after its First Commercial Sale and as part of its marketing and
product promotion, to the extent permitted by applicable law, to develop educational materials (e.g., brochures, website, etc.) directed to patients and physicians detailing the Licensed Products or medical aspects of the prophylactic
and therapeutic uses of the Licensed Products. 

  

	11.	 INFRINGEMENT AND PATENT ENFORCEMENT 

 

	 	11.1	 Leidos Biomedical and the Licensee agree to notify each other promptly of each infringement or possible
infringement of the Licensed Patent Rights, as well as, any facts which may affect the validity, scope, or enforceability of the Licensed Patent Rights of which either party becomes aware. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 11 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 11 of 28] ●

	 	11.2	 Pursuant to this Agreement and the provisions of 35 U.S.C. Chapter 29, the Licensee may:

  

	 	(a)	 bring suit in its own name, at its own expense, and on its own behalf for infringement of presumably valid
claims in the Licensed Patent Rights; 

  

	 	(b)	 in any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature
recoverable for the infringement; or 

  

	 	(c)	 settle any claim or suit for infringement of the Licensed Patent Rights provided, however,
that Leidos Biomedical shall have the first right to take such actions; and 

  

	 	(d)	 if the Licensee desires to initiate a suit for patent infringement, the Licensee shall notify
Leidos Biomedical in writing. If Leidos Biomedical does not notify the Licensee of its intent to pursue legal action within [***] days, the Licensee shall be free to initiate suit. Leidos Biomedical shall have a continuing right to join the
suit. The Licensee shall take no action to compel Leidos Biomedical either to initiate or to join in any suit for patent infringement. In all cases, the Licensee agrees to keep Leidos Biomedical reasonably apprised of the status and progress
of any litigation. Before the Licensee commences an infringement action, the Licensee shall notify Leidos Biomedical and give careful consideration to the views of Leidos Biomedical and to any potential effects of the litigation on the
public health in deciding whether to bring suit. 

  

	 	11.3	 In the event that a declaratory judgment action alleging invalidity or non-infringement of any of the
Licensed Patent Rights shall be brought against the Licensee or raised by way of counterclaim or affirmative defense in an infringement suit brought by the Licensee under Paragraph 11.2, pursuant to this
Agreement and the provisions of 35 U.S.C. Chapter 29 or other statutes, the Licensee may: 

  

	 	(a)	 defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the
Licensed Patent Rights; 

  

	 	(b)	 in any suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and awards of
whatever nature recoverable for the infringement; and 

  

	 	(c)	 settle any claim or suit for declaratory judgment involving the Licensed Patent
Rights-provided, however, that Leidos Biomedical shall have the first right to take these actions and shall have a continuing right to intervene in the suit; and 

 

	 	(d)	 if Leidos Biomedical does not notify the Licensee of its intent to respond to the legal action within a
reasonable time, the Licensee shall be free to do so. If the Licensee elects not to defend against the declaratory judgment action, Leidos Biomedical, at its option, may do so at its own expense. In all cases, the Licensee agrees to keep
Leidos Biomedical reasonably apprised of the status and progress of any litigation. Before the Licensee commences an infringement action, the Licensee shall notify Leidos Biomedical and give careful consideration to the views of Leidos
Biomedical and to any potential effects of the litigation on the public health in deciding whether to bring suit. 

  

	 	11.4	 In any action under Paragraphs 11.2 or 11.3 the expenses including costs, fees, attorney fees, and
disbursements, shall be paid by the Licensee. The value of any recovery made by the Licensee through court judgment or settlement shall be treated as Net Sales and subject to earned royalties. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 12 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 12 of 28] ●

	 	11.5	 Leidos Biomedical shall cooperate fully with the Licensee in connection with any action under Paragraphs
11.2 or 11.3. Leidos Biomedical agrees promptly to provide access to all necessary documents and to render reasonable assistance in response to a request by the Licensee. 

 

	12.	 NEGATION OF WARRANTIES AND INDEMNIFICATION 

 

	 	12.1	 Leidos Biomedical offers no warranties, other than that those facts specified in Article 1 are accurate and
that Leidos Biomedical has not, as of the Effective Date, granted any rights to any third party under the Licensed Patent Rights. 

  

	 	12.2	 Leidos Biomedical does not warrant the validity of the Licensed Patent Rights and makes no
representations whatsoever with regard to the scope of the Licensed Patent Rights, or that the Licensed Patent Rights may be exploited without infringing other patents or other intellectual property rights
of third parties. 

  

	 	12.3	 LEIDOS BIOMEDICAL MAKES NO WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE LICENSED PATENT RIGHTS OR TANGIBLE MATERIALS RELATED THERETO. 

  

	 	12.4	 Leidos Biomedical does not represent that it shall commence legal actions against third parties infringing the
Licensed Patent Rights. 

  

	 	12.5	 The Licensee shall indemnify and hold Leidos Biomedical, its employees, students, fellows, agents, and
consultants, and that U.S. Government harmless from and against all third party liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of:

  

	 	(a)	 the use by or on behalf of the Licensee, its sublicensees, directors, employees, or third parties of any
Licensed Patent Rights; or 

  

	 	(b)	 the design, manufacture, distribution, or use of any Licensed Products, Licensed
Processes or materials by the Licensee, or other products or processes developed in connection with or arising out of the Licensed Patent Rights. 

 

	 	12.6	 The Licensee agrees to maintain a liability insurance program consistent with sound business practice and with
sufficient coverage to meet the requirements of this Paragraph 12.5. 

  

	13.	 TERM, TERMINATION, AND MODIFICATION OF RIGHTS 

 

	 	13.1	 This Agreement is effective when signed by all parties, unless the provisions of Paragraph 14.16 are not
fulfilled, and shall extend to the expiration of the last to expire of the Licensed Patent Rights unless sooner terminated as provided in this Article 13. 

 

	 	13.2	 In the event that the Licensee is in default in the performance of any material obligations under this
Agreement, including but not limited to the obligations listed in Paragraph 13.5, and if the default has not been remedied within [***] days after the date of notice in writing of the default, Leidos Biomedical may terminate this
Agreement by written notice and pursue outstanding royalties owed through other procedures, including but not limited to judicial collection. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 13 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 13 of 28] ●

	 	13.3	 In the event that the Licensee becomes insolvent, files a petition in bankruptcy, has such a petition
filed against it, determines to file a petition in bankruptcy, or receives notice of a third party’s intention to file an involuntary petition in bankruptcy, the Licensee shall immediately notify Leidos Biomedical in writing.

  

	 	13.4	 The Licensee shall have a unilateral right to terminate this Agreement or any licenses in any
country or territory by giving Leidos Biomedical [***] days written notice to that effect, 

  

	 	13.5	 Leidos Biomedical shall specifically have the right to terminate or modify (subject to Licensee’s
agreement to such modification), at its option, this Agreement, using the process set forth in Section 13.2, if Leidos Biomedical determines that the Licensee; 

 

	 	(a)	 is not using commercially reasonable efforts to execute the Commercial Development Plan
submitted with its request for a license and the Licensee cannot otherwise demonstrate that the Licensee has taken, or can be expected to take within a reasonable time, effective steps to achieve the Practical Application
of the Licensed Products or the Licensed Processes; 

  

	 	(b)	 has not achieved the Benchmarks as may be modified under Paragraph 9.2; 

 

	 	(c)	 has willfully made a false statement of, or willfully omitted a material fact in the license application or in
any report required by this Agreement; 

  

	 	(d)	 has committed a material breach of a covenant or agreement contained in this Agreement.

  

	 	13.6	 In making the determination referenced in Paragraph 13.5, Leidos Biomedical shall take into account the normal
course of such commercial development programs conducted with sound and reasonable business practices and judgment and the annual reports submitted by the Licensee under Paragraph 9,2, Prior to invoking termination or modification of this
Agreement under Paragraph 13.5, Leidos Biomedical shall give written notice to the Licensee providing the Licensee specific notice of, and a [***] day opportunity to respond to, Leidos Biomedical’s concerns as to the items
referenced in 13.5(a)-13.5(g). If the Licensee fails to alleviate Leidos Biomedical’s concerns as to the items referenced in 13.5(a)-13.5(g) or fails to initiate corrective action to Leidos Biomedical’s satisfaction, Leidos
Biomedical may terminate this Agreement. 

  

	 	13.7	 When the public health and safety so require, and after written notice to the Licensee providing (he
Licensee a [***] day opportunity to respond. Leidos Biomedical shall have the right to require the Licensee to grant sublicenses to responsible applicants, on reasonable terms, in any Licensed Fields of Use
under the Licensed Patent Rights, unless the Licensee can reasonably demonstrate that the granting of the sublicense would not materially increase the availability to the public of the subject matter of the
Licensed Patent Rights. Leidos Biomedical shall not require the granting of a sublicense unless the responsible applicant has first negotiated in good faith with the Licensee. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 14 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 14 of 28] ●

	 	13.8	 Within [***] days of expiration or termination of this Agreement under this Article 13, a final report
shall be submitted by the Licensee. Any royalty payments, including those incurred but not yet paid (such as the full minimum annual royalty), and those related to patent expenses, due to Leidos Biomedical shall become immediately due and
payable upon termination or expiration. If terminated under this Article 13, sublicensees may elect to convert their sublicenses to direct licenses with Leidos Biomedical pursuant to Paragraph 4.3. Unless otherwise specifically provided for under
this Agreement, upon termination or expiration of this Agreement, the Licensee shall return all Licensed Products or other materials included within the Licensed Patent Rights to Leidos Biomedical or
provide Leidos Biomedical with certification of the destruction thereof. The Licensee may not be granted additional Leidos Biomedical licenses if the final reporting requirement is not fulfilled. 

 

	14.	 GENERAL PROVISIONS 

 

	 	14.1	 Neither party may waive or release any of its rights or interests in this Agreement except in writing.
The failure of Leidos Biomedical to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right by Leidos Biomedical or excuse a similar subsequent failure to
perform any of these terms or conditions by the Licensee. 

  

	 	14.2	 This Agreement constitutes the entire agreement between the parties relating to the subject matter of
the Licensed Patent Rights, the Licensed Products and the Licensed Processes, and all prior negotiations, representations, agreements, and understandings are merged into, extinguished by, and
completely expressed by this Agreement. 

  

	 	14.3	 The provisions of this Agreement are severable, and in the event that any provision of this
Agreement shall be determined to be invalid or unenforceable under any controlling body of law, this determination shall not in any way affect the validity or enforceability of the remaining provisions of this Agreement.

  

	 	14.4	 If either party desires a modification to this Agreement, the parties shall, upon reasonable notice of
the proposed modification by the party desiring the change, confer in good faith to determine the desirability of the modification. No modification shall be effective until a written amendment is signed by the signatories to this Agreement or
their designees. 

  

	 	14.5	 The construction, validity, performance, and effect of this Agreement shall be governed by the laws of
the State of Maryland. 

  

	 	14.6	 All Agreement notices required or permitted by this Agreement shall be given by prepaid, first
class, registered or certified mail or by an express/overnight delivery service provided by a commercial carrier, properly addressed to the other party at the address designated on the following Signature Page, or to another address as may be
designated in writing by the other party. Agreement notices shall be considered timely if the notices are received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark
or dated receipt from a commercial carrier. Parties should request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as
proof of timely mailing. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 15 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 15 of 28] ●

	 	14.7	 This Agreement shall not be assigned or otherwise transferred (including any transfer by legal process or by
operation of law, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure or order of court) except to the Licensee’s Affiliate(s) or
successor-in-interest in connection with the sale of all or substantially all of Licensee’s stock or assets to which this Agreement pertains, in each case without
the prior written consent of Leidos Biomedical. Additionally, Leidos Biomedical may assign this Agreement to the successor-in-interest to the FFRDC contracts with the
NCI for the operation of the Frederick National Laboratory for Cancer Research. The parties agree that the identity of the parties is material to the formation of this Agreement and that the obligations under this Agreement are nondelegable. In the
event that the Leidos Biomedical approves a proposed assignment, the Licensee shall pay Leidos Biomedical, as an additional royalty, [***] percent ([***]%) of the fair market value of any consideration received for any assignment of this Agreement
within [***] days of the assignment. 

  

	 	14.8	 The Licensee agrees that if it uses any Leidos Biomedical supplied materials,
Licensee will comply with all applicable statutes, regulations, and guidelines. The Licensee agrees not to use the materials provided by Leidos Biomedical for research involving human subjects or clinical trials in the United States
without complying with 21 C.F.R. Part 50 and 45 C.F.R. Part 46. The Licensee agrees not to use the materials for research involving human subjects or clinical trials outside of the United States without notifying Leidos
Biomedical, in writing, of the research or trials and complying with the applicable regulations of the appropriate national control authorities. Written notification to Leidos Biomedical of research involving human subjects or clinical trials
outside of the United States shall be given no later than [***] days prior to commencement of the research or trials. 

  

	 	14.9	 The Licensee acknowledges that it is subject to and agrees to abide by the United States laws and
regulations (including the Export Administration Act of 1979 and Arms Export Control Act) controlling the export of technical data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of
these items may require a license from the appropriate agency of the U.S. Government or written assurances by the Licensee that it shall not export these items to certain foreign countries without prior approval of this agency. Leidos
Biomedical neither represents that a license is or is not required or that, if required, it shall be issued. 

  

	 	14.10	 The Licensee agrees to, to the extent required by applicable law, mark the Licensed
Products or their packaging sold in the United States with all applicable U.S. patent numbers and similarly to indicate “Patent Pending” status. All the Licensed Products manufactured in, shipped to, or sold in other
countries shall be marked in a manner to preserve Leidos Biomedical’s patent rights in those countries. 

  

	 	14.11	 By entering into this Agreement, Leidos Biomedical does not directly or indirectly endorse any product
or service provided, or to be provided, by the Licensee whether directly or indirectly related to this Agreement. The Licensee shall not state or imply that this Agreement is an endorsement by Leidos Biomedical, the U.S.
Government, or any Leidos Biomedical or Government employee. Additionally, the Licensee shall not use the names of Leidos Biomedical, Frederick National Laboratory for Cancer Research or of any unit of the Government or any of their
employees or agents in any advertising, promotional, or sales literature without the prior written approval of Leidos Biomedical. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 16 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 16 of 28] ●

	 	14.12	 The parties agree to attempt to settle amicably any controversy or claim arising under this Agreement or
a breach of this Agreement, except for appeals of modifications or termination decisions provided for in Article 13. The Licensee agrees first to appeal any unsettled claims or controversies to the designated Leidos
Biomedical official, or designee. If not resolved, Licensee Licensee may exercise any judicial remedies that may be available. 

  

	 	14.13	 Nothing relating to the grant of a license, nor the grant itself, shall be construed to confer upon any person
any immunity from or defenses under the antitrust laws or from a charge of patent misuse, and the acquisition and use of rights pursuant to 37 C.F.R. Part 404 shall not be immunized from the operation of state or Federal law by reason of the
source of the grant. 

  

	 	14.14	 Any forma! recordation of this Agreement required by the laws of any Licensed Territory as
a prerequisite to enforceability of the Agreement in the courts of any foreign jurisdiction or for other reasons shall be carried out by the Licensee at its expense, and appropriately verified proof of recordation shall be promptly
furnished to the Leidos Biomedical. 

  

	 	14.15	 Paragraphs 2, 4.3, 8.1, 9.5-9.8 (solely with respect to any Sales made by Licensee prior to the effective date
of such termination or expiration), 12.1-12.5 (with respect to Section 12.5, solely with respect to actions occurring during the Term), 13.8, and 14 of this Agreement shall survive the expiration or termination of this Agreement.

  

	 	14.16	 The terms and conditions of this Agreement shall, at Leidos Biomedical’s sole option, be considered
by Leidos Biomedical to be withdrawn from the Licensee’s consideration and the terms and conditions of this Agreement, and the Agreement itself to be null and void, unless this Agreement is executed by the
Licensee and a fully executed original is received by Leidos Biomedical within sixty (60) days from the date of the Leidos Biomedical’s signature found at the Signature Page. 

SIGNATURES BEGIN ON NEXT PAGE 

  
 CONFIDENTIAL 

Patent License Agreement – Exclusive 
 Page 17 of 28
[Final] [Theras] [Friday, December 14, 2018] 
 1 
 [Page 17 of
28] ● 

 SIGNATURE PAGE 

For Leidos Biomedical Research, Inc.: 
  

									
	 /s/ Ethan Dmitrovsky -S (Affiliate)
	 		 		 	 12.21.18

	Name	 		 		 		 	Date
	Title	 		 		 		 	
	Office	 		 		 		 	

 Mailing Address or E-mail Address for Agreement
notices and reports: 
 IP/SA, P.O. Box B, Frederick, MD 21702 

For the Licensee (Upon, information and belief, the undersigned expressly certifies or affirms that the contents of any statements of the
Licensee made or referred to in this document are truthful and accurate.): 
 by: 

 

									
	 /s/ Michael Henderson
	 		 		 	December 17th 2018
	Signature of Authorized Official	 		 		 	Date
				
	 Michael Henderson
	 		 		 	
	Printed Name	 		 		 	
				
	 SVP, Business Development & Operations
	 		 		 	
	Title	 		 		 		 	

  

									
	            	 	I.	 	Official and Mailing Address for Agreement notices:	  	
				
		 		 	 Eric Gomez
	  	
		 		 	Name	  	
				
		 		 	 VP of Business Development & Operations
	  	
		 		 	Title	  	
				
		 		 	Mailing Address	  	
				
		 		 	 75 Federal St. San Francisco. 94107
	  	
		 		 	  
	  	
		 		 	  
	  	
		 		 	  
	  	

									
					
		 		 	Email Address:	  	 [***]
	  	
					
		 		 	Phone:	  	 [***]
	  	
					
		 		 	Fax:	  	 N/A
	  	

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 18 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 18 of 28] ●

	 	II.	 Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty
payments) 

  

			
	 Tina Kraft
	 	
	Name	 	
		
	 Accounting
	 	
	Title	 	
		
	Mailing Address	 	
		
	 421 Kipling St
	 	
		
	 Palo Alto, CA 94301
	 	
		
	  
	 	
		
	  
	 	

  

					
	Email Address:	  	 accounting@theras.com
	  	
			
	Phone:	  	 650-391-9740
	  	
			
	Fax:	  	 650-989-1331
	  	

  
 CONFIDENTIAL 

Patent License Agreement – Exclusive 
 Page 19 of 28
[Final] [Theras] [Friday, December 14, 2018] 
 1 
 [Page 19 of
28] ● 

 APPENDIX A – PATENT(S) OR PATENT APPLICATION(S) 

Patent(s) Or Patent Application(s): 
  

	I.	 [***] 

  

	II.	 [***] 

  

	III.	 [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 20 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 20 of 28] ●

 APPENDIX B – LICENSED FIELDS OF USE AND TERRITORY 

 

	I	 Licensed Fields of Use: 

 

	 	(a)	 Prophylactic, therapeutic and diagnostic use in humans and animals 

 

	II.	 Licensed Territory: Worldwide 

  
 CONFIDENTIAL 

Patent License Agreement – Exclusive 
 Page 21 of 28
[Final] [Theras] [Friday, December 14, 2018] 
 1 
 [Page 21 of
28] ● 

 APPENDIX C - ROYALTIES 

Royalties: 
  

	I.	 The Licensee agrees to pay to Leidos Biomedical a noncreditable, nonrefundable license issue
royalty in the amount of One Hundred and Fifty Thousand dollars ($150,000) within sixty (60) days from the effective date of this Agreement. 

  

	II.	 The Licensee agrees to pay to Leidos Biomedical a nonrefundable minimum annual royalty in the amount of
[***] dollars ([***]) as follows: 

  

	 	(a)	 The first minimum annual royalty is due within sixty (60) days of the effective date of this
Agreement and may be prorated according to the fraction of the calendar year remaining between the effective date of this Agreement and the next subsequent January 1; and 

 

	 	(b)	 Subsequent minimum annual royalty payments are due and payable on January 1 of each calendar year and may
be credited against any earned royalties due for sales made in that year. 

  

	III.	 The Licensee agrees to pay Leidos Biomedical earned royalties of [***] percent ([***]%) on Net
Sales by or on behalf of the Licensee and its sublicensees. For a Combination Product, Net Sales shall be calculated as: 

A/(A+B) x [Net Sales, calculated without regard to this formula, of the Combination Product], 

Where: 
  

	 	(i)	 “A” is the total average Net Sales price per unit of each Licensed Product contained within or used
in the Combination Product when sold separately; and 

  

	 	(ii)	 “B” is either (a) the total average Net Sales price per unit if the Combination Product
Component is sold separately by Licensee, a Sublicensee, or Affiliate; or (b) the total average gross invoice price (specifically for the Combination Product Component and not for any services provided or research and development costs, etc.)
less deductions per unit if the Combination Product Component is sold by a third party; of each Combination Product Component contained within or used in the Combination Product when sold separately. Provided however, that in no event shall Net
Sales for a Combination Product be less than fifty percent (50%) of “A” (as defined in the calculation above). 

  

	 	a.	 If either Licensed Product or the Combination Product Component is not sold separately, then A and/or B (as
applicable) shall be calculated based on the gross invoice price less deductions for other products of the same or similar kind and quality, sold in similar quantities, currently being offered for Sale by Licensee or any Sublicensee. Where such
similar products are not currently being offered for Sale by Licensee or Sublicensee, A and/or B (as applicable) shall be calculated based on the average gross selling price or published gross list price for sales to an unaffiliated third party in
an arm’s length transaction, less deductions at which products of the same or similar kind and quality, sold in similar quantities, are then 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 22 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 22 of 28] ●

	 	
currently being offered for Sale by other manufacturers or other parties. Where such products are not currently sold or offered for Sale by Licensee or any Sublicensee, nor by any other
manufacturer or other party, then A and/or B (as applicable) will be one hundred fifty percent (150%) of as relevant, Licensee’s or any Sublicensee’s cost of manufacture of the relevant Licensed Product or Combination Product Component,
determined in accordance with generally accepted accounting principles (“GAAP”); and 

  

	 	b.	 In such calculaton in no event shall Net Sales of a Licensed Product be disproportion ally discounted as
compared to the Combination Product Component. 

  

	IV.	 The Licensee agrees to pay Leidos Biomedical Benchmark royalties within [***] days of achieving each
Benchmark, with each payment due only once under this Agreement: 

 For the first indication for first Licensed Product: 

 

	 	(a)	 [***] upon [***]; 

  

	 	(b)	 [***] upon [***]; 

  

	 	(c)	 [***] upon [***]; 

  

	 	(d)	 [***] upon [***]; 

  

	 	(e)	 [***] upon [***]; and 

 

	 	(f)	 [***] upon [***]. 

For the second indication for each Licensed Product: 
  

	 	(a)	 [***] upon [***]; 

  

	 	(b)	 [***] upon [***]; 

  

	 	(c)	 [***] upon [***]; and 

 

	 	(d)	 [***] upon [***]. 

For the avoidance of doubt, each of the Benchmark payments set forth in this Appendix C will be payable with respect to each Licensed Product and regardless
of whether the applicable Benchmark event has been achieved by Licensee, Sublicensee, or any Affiliate, provided that if Licensee discontinues the development and/or commercialization of a particular Licensed Product and instead develops and/or
commercializes another Licensed Product in place of such discontinued Licensed Product, then Licensee shall not be required to make any Benchmark payments for such second Licensed Product for any Benchmark events that have already triggered
Licensee’s payment obligations for the discontinued Licensed Product for that particular indication. All Benchmark payments set forth in Appendix C are due within thirty (30) days of the occurrence. No benchmark payment will be due for any
subsequent Licensed Product or subsequent indication(s) for the same Licensed Product. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 23 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 23 of 28] ●

	V.	 The Licensee agrees to pay Leidos Biomedical additional sublicensing royalties of [***] Percent
([***]) on the fair market value of any consideration received for and attributable to the granting each third party sublicense within [***]) days of the execution of each sublicense if such sublicense is granted [***], [***] percent ([***]%) if
such sublicense is granted [***], and [***] percent ([***]%) if such sublicense is granted [***]. Sublicensing revenues means amounts (including, without limitation, any licensing or optioning fees, or license maintenance fees, or milestone
payments, and fair market value of any non-cash consideration), received by or payable to the Licensee from any sublicensee in consideration for the rights granted under a sublicense of the Licensee’s
rights under this Agreement, provided that sublicensing revenues will not include amounts received by or payable to the Licensee that are reasonably and fairly attributable to any of the following to the extent that each is bona fide; (a) [***], (b)
amounts received by the Licensee as [***] of the Licensee; (c) [***]; (d) [***], and (e) [***], and (f) [***]. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 24 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 24 of 28] ●

 APPENDIX D-BENCHMARKS AND PERFORMANCE

 The Licensee agrees to the following Benchmarks for its performance under this Agreement and, within thirty (30) days
of achieving a Benchmark, shall notify Leidos Biomedical that the Benchmark has been achieved. 
  

	I.	 [***] 

  

	II.	 [***] 

  

	III.	 [***] 

The above benchmarks shall be extended for regulatory and scientific reasons or other factors outside the reasonable control of Licensee.
Licensee shall also have the right to extend any particular benchmark (and the subsequent benchmarks) by [***] by [***]. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 25 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 25 of 28] ●

 APPENDIX E - COMMERCIAL DEVELOPMENT PLAN 

Theras will endeavor to achieve milestones as stated under Appendix D, and will [***], using commercially reasonable efforts to [***]. Ideally, Theras will
identify and [***]. This is anticipated as [***]. Theras will initially seek approval in [***]. 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 26 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 26 of 28] ●

 APPENDIX F - EXAMPLE ROYALTY REPORT 

Required royalty report information includes: 
  

	 	•	 	 License reference number ([***]) 

) 
  

	•	 	 Reporting period 

  

	•	 	 Catalog number and units sold of each Licensed Product (domestic and foreign) 

 

	•	 	 Gross Sales per catalog number per country 

 

	•	 	 Total Gross Sales 

  

	•	 	 Itemized deductions from Gross Sales 

 

	•	 	 Total Net Sales 

  

	•	 	 Earned Royalty Rate and associated calculations 

 

	•	 	 Gross Earned Royalty 

  

	•	 	 Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made 

 

	•	 	 Net Earned Royalty due 

Example 
  

									
	 Catalog Number
	  	Product Name	  	 Country
	  	Units Sold	  	 Gross Sales
(US$)

	1	  	A	  	US	  	[***]	  	[***]
	1	  	A	  	UK	  	[***]	  	[***]
	1	  	A	  	France	  	[***]	  	[***]
	2	  	B	  	US	  	[***]	  	[***]
	3	  	C	  	US	  	[***]	  	[***]
	4	  	D	  	US	  	[***]	  	[***]
		  	 Total Gross Sales
	  	[***]
		  	Less Deductions:	  	
		  	 Freight
	  	[***]
		  	 Returns
	  	[***]
		  	 Total Net Sales
	  	[***]
		  	 Royalty Rate
	  	[***]
		  	 Royalty Due
	  	[***]
		  	Less Creditable Payments	  	[***]
		  	 Net Royalty Due
	  	       0

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 27 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 27 of 28] ●

 APPENDIX G - ROYALTY PAYMENT OPTIONS 

New Payment Options Effective March 2018 

The License Number MUST appear on payments, reports and correspondence. 

License Number: [***] 
 To Mail Checks: 

General Accounting 
 Leidos Biomedical Inc. 

1050 Boyles Street 
 Frederick, Maryland 21702 

For wires: 
 BANK: CITIBANK, N.A. 

388 Greenwich St. 
 New York, NY 10013  

FED ABA#: [***]  
 SWIFTCODE [***] 

 ACCOUNT NAME: Leidos Biomedical Research, Inc.  

ACCOUNT #: [***] 

  

	
	  

[***]   Certain information in this document has been omitted from this exhibit because it is
both (i) not material and (ii) would be competitively harmful if publicly disclosed.
  

	  
 CONFIDENTIAL

Patent License Agreement – Exclusive
 Page 28 of 28
[Final] [Theras] [Friday, December 14, 2018]
 1
  

[Page 28 of 28] ●EX-10.17

 Exhibit 10.17 

 

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and
(ii) would be competitively harmful if publicly disclosed. 

  

 
  

LIFE TECHNOLOGIES CELL LINE LICENSE AGREEMENT 

This Cell Line License Agreement (the “Agreement” or the “License”), effective as of November 15, 2018 (the
“Effective Date”), by and between Life Technologies Corporation, a Delaware corporation having its principal place of business at 5781 Van Allen Way, Carlsbad, CA 92008 USA (“Life”), and BridgeBio Services, Inc., a
Delaware Limited Liability Company having its principal place of business at 421 Kipling Street, Palo Alto, California 94301, USA (“Licensee”). Each of Life and Licensee may be referred to herein as a “Party” and
collectively as the “Parties”. 
 BACKGROUND RECITALS 

WHEREAS, Life has developed certain Expi293FTM lines (cGMP banked) (“Life Cells”, as
defined below); 
 WHEREAS, the Parties entered into that certain Cell Line Evaluation License Agreement, effective as of August 31, 2018,
(“Evaluation Agreement”) to evaluate the use of the Life Cells for Licensee’s purposes; 
 WHEREAS, Licensee desires to obtain a non-exclusive license to use such Life Cells for producing genetically engineered adeno-associated virus (“AAV”) particles for certain purposes, including, but not limited to, research, development
(including human clinical trials), manufacturing and commercial uses; and 
 WHEREAS, Life is willing to grant to Licensee a
non-exclusive license to use Life Cells under the terms and conditions set forth hereunder. 

AGREEMENT 
 NOW THEREFORE, in
consideration of the premises and of the mutual covenants and agreements contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties intending to be legally bound agree as
follows: 
 1. Definitions. For the purposes of this Agreement, the terms set forth hereinafter are defined as follows: 

1.1 “Additional License Fee” has the meaning set forth in Section 3.2. 

1.2 “Additional Licensee Product(s)” means products that (a) meet the requirements of
Subsections (i)-(iii) of Licensee Product(s)’ definition and (b) are added to the Agreement after the Effective Date in accordance with Section 2.2 (subject to the payment of the corresponding fees set forth
in Section 3). 

  
 Page 1 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 1.3 “Affiliate” means with respect to a particular Party, a person,
corporation, partnership, or other entity that is controlled by such Party, for only so long as such control exists. For the purposes of this definition, the word “Control” means the actual power, either directly or indirectly
through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of more than fifty percent (50%) of the voting stock of such entity (or such lesser percentage which is the
maximum allowed to be owned by a foreign corporation in a particular jurisdiction), or by contract or otherwise. 
 1.4 “Authorized
Affiliate(s)” mean those Licensee Affiliates listed in Exhibit A attached hereto, which may be amended and updated from time to time in accordance with Section 2.1(b). 

1.5 “Business Day” means a day other than Saturday, Sunday or any other day on which commercial banks located in the U.S. are
authorized or obligated by Laws to close. 
 1.6 “Cell Line Documentation Package” or “CLDP” means a single
document package that details the source, history and generation of one (1) specific lot of Life Cells, including the preparation, characterization and testing of the seed, master, working and/or catalog cell banks (as applicable) for such Life
Cells. The CLDP is subject to Life copyrights and to the terms and conditions contained in this Agreement. 
 1.7 “Change of
Control” means with respect to an entity, the acquisition by any person or group, directly or indirectly, of the beneficial ownership of more than fifty percent (50%) of the total voting power of such entity; (ii) through a merger of
such entity into another person or entity; and (iii) through the sale, lease or transfer of all or substantially all of the assets of such entity to any person or entity in one or a series of related transactions. For the sake of
clarification, a Change of Control shall not be deemed to have occurred if Licensee and/or one or more of its Authorized Affiliates files for an Initial Public Offering and becomes a publicly traded company. 

1.8 “Claims” has the meaning set forth in Section 11.1 

1.9 “Confidential Information” has the meaning set forth in Section 5.1. 

1.10 “Cure Period” has the meaning set forth in Section 7.3. 

1.11 “Development” with a correlative meaning for “Develop”, means any and all activities relating to
preparing and conducting preclinical testing, toxicology testing, human clinical studies, and regulatory activities (e.g., regulatory applications) with respect to Licensee Product, together with the testing, analysis, expression, manufacture,
production and storage of the Licensee Product solely for the purpose of conducting the foregoing activities. 
 1.12
“Distributor” means a Third Party to whom, pursuant to a written agreement with such Third Party, Licensee sells Licensee Products under Licensee’s Marks for resale to customers. In no event shall any Third Party have the
rights to make modifications to any Licensee Products or part thereof, including relabeling such Licensee Products or part thereof, except for placement of the Distributor’s name on such Licensee Product to comply with any country-specific
regulatory requirements. 
 1.13 “FDA” means the U.S. Food and Drug Administration or any successor regulatory agency or
body thereto. 

  
 Page 2 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 1.14 “First Commercial Sale” means the first sale or other transfer for
consideration for use or consumption by the customer of a Licensee Product in the Territory after marketing approval by a Regulatory Authority has been obtained. 

1.15 “First Licensee Product” means a product that (a) meets the requirements of Subsections (i)-(ii) of
Licensee Product(s)’ definition and (b) is used only in the treatment of, or in the preparation of the treatment of, 21-hydroxylase deficiency in human patients through Licensee’s
proprietary methodologies. 
 1.16 “Governmental Authority” means any multi-national, federal, state, local, municipal or
other government authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, court, or other tribunal). 

1.17 “IND” means an Investigational New Drug Application, as defined in the U.S. Federal Food, Drug and Cosmetic Act, with the
FDA or any corresponding application in any country or regulatory jurisdiction other than the U.S. 
 1.18 “Initial License
Fee” has the meaning set forth in Section 3.1. 
 1.19 “Laws” means all applicable laws, statutes, rules,
regulations, ordinances, compliance guidance in final form, and other pronouncements, all as amended from time to time, having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision,
domestic or foreign. 
 1.20 “Licensee’s Marks” means Licensee’s trademarks and trade names, whether registered or
not, and Licensee’s brands and logos. 
 1.21 “Licensee Product(s)” means products, which are
(i) genetically engineered AAV particles, including therapeutically active formulations of such products, (ii) developed and manufactured by Licensee or its Authorized Affiliates, or on behalf of Licensee or its Authorized
Affiliates by Service Provider(s), through the use of Life Cells, (iii) used only in the treatment of, or in the preparation of the treatment of, a certain indication in human patients through Licensee’s proprietary methodologies,
and are (iv) a First Licensee Product or an Additional Licensee Product. 
 1.22 “Life Cells” means the Expi293FTM cell lines (cGMP banked) (with catalog number 100044202) transferred to Licensee or its Authorized Affiliates by Life or a Life Affiliate prior to the Effective Date under the Evaluation Agreement;
and (ii) any and all progeny thereof generated by Licensee or its Authorized Affiliates 
 1.23 “Life
Indemnitees” has the meaning set forth in Section 11.1. 
 1.24 “Life Rights” means one or more of the
intellectual property rights licensed to or owned by Life, to the extent that they relate to the manufacture, use, sale, or import of Licensee Product or the use of the CLDP in accordance with the license grant, selected from the following:
(i) all proprietary rights of Life in and to the Life Cells including biological materials rights; (ii) all proprietary know-how, trade secrets, data, test results, techniques, procedures, compositions, methods, formulas, protocols and
information, in each case developed, owned, or controlled by Life or its Affiliates and (iii) all copyrights, whether or not such copyrights are registered with the U.S. Library of Congress or other governmental body by Life or its Affiliate, which
are associated with the CLDP. 

  
 Page 3 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 1.25 “Non-Compliant Entity” has the
meaning set forth in Section 7.3. 
 1.26 “Regulatory Authorization” means any approval or authorization of any
Regulatory Authority in a particular jurisdiction that is necessary for the Development, manufacture, use, storage, import, transport, marketing, sale, or other commercialization of Licensee Products in such jurisdiction in accordance with Laws.

 1.27 “Regulatory Authority” means any applicable Governmental Authority involved in granting Regulatory Authorization in
any country or jurisdiction, including Without limitation, in the U.S., the FDA and any other applicable Governmental Authority having jurisdiction over the Life Cells or over Licensee Products. 

1.28 “Regulatory Filings” means regulatory applications, submissions, notifications, registrations, Regulatory Authorizations,
or other submissions made to or with a Regulatory Authority that are necessary or reasonably desirable in order to research, Develop, manufacture, market, sell or otherwise commercialize Licensee Products in a particular country or jurisdiction.

 1.29 “Service Provider” means a Third Party, including, but not limited to a contractor, subcontractor or contract
service organization, that performs services for consideration on behalf of Licensee or its Authorized Affiliate, and with whom Licensee or its Authorized Affiliate has entered into a written agreement for the provision of services for Licensee or
its Authorized Affiliate that employs Life Cells solely for the benefit of Licensee or such Authorized Affiliate of Licensee, for purposes which include, without limitation, the research, Development, testing, analysis, expression, assay,
manufacture, production and storage of Licensee Products. 
 1.30 “Term” has the meaning set forth in
Section 7.1. 
 1.31 “Territory” means worldwide. 

1.32 “Third Party” means any person or entity other than Life, Affiliates of Life, Licensee, and Authorized Affiliates of
Licensee. 
 1.33 “U.S.” means the United States of America. 

2. Grant of License; Authorized Affiliates; Service Providers; CLDP. 

2.1 Grant of License. 
 (a)
For each Licensee Product for which appropriate payments of the Initial License Fee and Additional License Fee have been made (as set forth in Section 3) and subject to the terms and conditions of this Agreement, Life hereby grants to Licensee,
and Licensee hereby accepts from Life, a worldwide, non-exclusive, royalty-free, non-sublicensable, non-transferable (except as set forth in Section 2.1(d) hereof) license in the Territory under the Life Rights for Licensee to:
(i) use the Life Cells to Develop Licensee Products and to have Service Providers use the Life Cells to Develop Licensee Products for or on behalf of Licensee only, and (ii) use the Life Cells to make, have made by Services
Providers, sell and have sold by Distributors, offer for sale, import and export such Licensee Products, all solely under Licensee’s Marks. 

  
 Page 4 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 (b) Use by Authorized Affiliates. Any rights of Licensee under this Agreement may be
exercised and any obligations of Licensee under this Agreement may be performed by any Authorized Affiliate of Licensee to the extent that (i) the Authorized Affiliate remains an Affiliate of Licensee and (ii) such Authorized
Affiliate’s name and address is listed on Exhibit A. Licensee may, from time to time after the Effective Date, add additional Affiliates to the list of Authorized Affiliates set forth in Exhibit A by providing a copy of such
updated Exhibit A to Life pursuant to Section 12.2 of this Agreement. Upon Life’s receipt of the updated Exhibit A such Affiliate will be considered an Authorized Affiliate hereunder. Licensee hereby
unconditionally guarantees the compliance with and performance by its Authorized Affiliates of all applicable provisions of this Agreement and will be responsible and jointly and severally liable for all of its and its Authorized Affiliates’
obligations due pursuant to this Agreement. A breach of this Agreement by any of Authorized Affiliates will be deemed a breach by Licensee. 

(c) Use by Service Providers. For clarity, nothing herein will preclude Licensee from entering into, or will require consent from Life
with respect to, agreements with any Service Providers to transfer Life Cells to Service Providers, for use by such Service Providers for purposes which include, without limitation, the research and Development of Licensee Products in accordance
with the rights granted hereunder, provided that each such Service Provider to which Life Cells are transferred after the Effective Date agrees in writing: 

(i) only to use such Life Cells on behalf of Licensee as provided hereunder; 

(ii) not to transfer Life Cells to, or use Life Cells on behalf of, any Third Party; 

(iii) not to use Life Cells for the benefit of such Service Provider other than such use on behalf of Licensee hereunder; and 

(iv) to return to Licensee or destroy all Life Cells in its possession upon completion or termination of its activities on behalf of Licensee,
and to certify such return or destruction in writing to Licensee (with a copy of such certification provided to Life upon request). 
 Licensee shall
promptly notify Life once it becomes aware that any Service Provider is using Life Cells other than as permitted under this Agreement. Licensee agrees that its continued employment of a Service Provider when Licensee and/or its Authorized Affiliates
are aware or should be aware that such Service Provider is using Life Cells other than as permitted hereunder, if not cured as provided under Section 7.3, shall constitute a material breach by Licensee under this Agreement. Notwithstanding the
foregoing, Licensee shall remain responsible for its own and its Service Providers’ performance under this Agreement 
 (d)
Sublicensing; Assignment; Transferability. No licenses provided under this Agreement may be sublicensed, assigned, or otherwise transferred by Licensee except in accordance with Section 8 below. Except as set forth in
Section 2.1(c) hereof, Licensee shall have no right to transfer Life Cells to any Third Party under this Agreement 
 (e) Cell Line
Documentation Package. 
 (i) Licensee’s payment of the Initial License Fee set forth in Section 3.1 of this Agreement
includes the right for Licensee to receive one (1) copy of a CLDP for one (1) specified lot of Life Cells. 

  
 Page 5 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 (ii) Subject to the full payment of the Initial License Fee, Life will send Licensee one
(1) copy of a CLDP which will include the cell line specific part number 100044202 and lot number 556726-MCB1 of Life Cells, no later than ten (10) Business Days after Life’s receipt of the Initial License Fee. 

(iii) In addition to any other rights and licenses granted under this Agreement, Life additionally hereby grants to Licensee, and Licensee
hereby accepts from Life, a worldwide, royalty-free, non-exclusive, non-transferable, non-sublicensable license under Life Rights
for Licensee to use CLDP solely for the purpose of applying for, obtaining and maintaining Regulatory Authorizations for Licensee Products. Except as otherwise stated in this Section 2.1(e), Licensee may not transfer or disclose the CLDP
to any Service Provider or any other Third Party. 
 (iv) For the avoidance of doubt, Life is under no obligation to deliver the CLDP to
Licensee prior to Life’s receipt of the Initial License Fee. For clarity, Licensee acknowledges and agrees that (a) neither Life nor any of its Affiliates shall be under any obligation to provide to Licensee any documentation or
information pertaining to Life Cells (including, without limitation, other lots of Life Cells) other than the CLDP sent by Life to Licensee for the specific lot of Life Cells, and (b) the CLDP provided by Life to Licensee shall be deemed
Confidential Information under this Agreement. 
 (v) If Licensee desires to obtain a license to use additional CLDP(s) for additional lots
of Life Cells, Licensee will pay to Life an amount of [***] USD ($[***]) (“Additional CLDP Fee”), which is not included in the fees set forth below in Section 3. Licensee will send such request in writing to Life with
payment of the Additional CLDP Fee for each such additional CLDP requested, and Life will send such additional CLDP(s) to Licensee within forty-five (45) days of Life’s receipt of the Additional CLDP Fee(s) (“Additional
CLDP”). Terms governing Licensee’s use of Additional CLDP(s) are set forth in this Section 2.1(e). 
 (f) No
Other Rights Granted. No other rights are conveyed to Licensee by Life by implication, estoppel or otherwise. 
 2.2 Additional
Licensee Products. 
 (a) At any time during the Term and subject to Section 2.2(d), Licensee may provide Life with a written
request (“Request Notice”) to add a Licensee Product to this Agreement (“Proposed Licensee Product”). The Request Notice will include details relating to the Proposed Licensee Product and its intended use, including
the specific indication that the Proposed Licensee Product would be used to treat. Any information provided by Licensee will be subject to confidentiality obligations and will only be used for the purposes of this Section 2.2. 

 

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and
(ii) would be competitively harmful if publicly disclosed. 

  
 Page 6 of 21 

 (b) Within thirty (30) days after receiving the Request Notice, Life will notify
Licensee in writing of its acceptance or rejection of the request to add such Proposed Licensee Product. Life may not reject any request to add a Proposed Product, unless, at such time: (a) Life is subject to a contractual obligation
between Life and a Third Party that would preclude Life from granting a license under Section 2.1 with respect to the Proposed Licensee Product, (b) Life is engaged in bona fide negotiations with a Third Party that would
preclude Life from granting a license under Section 2.1 with respect to the Proposed Licensee Product, or (c) Licensee is in material breach of the terms of this Agreement, in which cases, the request to add the Proposed
Licensee Product will be rejected. 
 (c) Within thirty (30) days from Life’s acceptance, Licensee may exercise its right to add
the Proposed Licensee Product to this Agreement by notifying Life that it is adding the Proposed Licensee Product to this Agreement and remitting the applicable Additional License Fee as set forth in Section 3.2, concurrent with such
notice. 
 (d) Licensee must add Licensee Products to this Agreement, in accordance with this Section 2.2(a)-(c), at least thirty
(30) days prior to the (i) transfer of the Proposed Licensee Product to Service Providers for development purposes on behalf of Licensee, or (ii) initiating a first clinical trial relating to the Proposed Licensee
Product. 
 2.3 Limitations. Licensee acknowledges and agrees that Licensee does not acquire any rights hereunder to: 

(a) transfer Life Cells to any Third Party other than its Service Providers or the Service Providers of its Authorized Affiliates as
specifically set forth in Section 2.1; 
 (b) sell or offer to sell Life Cells to any Third Party; 

(c) directly administer the Life Cells into humans or animals; or 

(d) direct the replication of or the use of the Life Cells for any purpose other than as set forth in Section 2.1 or as otherwise
specified herein. 
 2.4 Audits. Upon Life’s request provided with reasonable prior written notice, Licensee will allow an
appropriately qualified independent Third Party selected by Life and reasonably accepted by Licensee (the “Auditor”) to visit Licensee’s facilities during normal business hours to examine Licensee’s manufacturing records
that are related to the submission of a Regulatory Filing to a Regulatory Authority with respect to a Licensee Product and make copies of relevant records as reasonably required to determine that Licensee is carrying out its obligations in
compliance with this Agreement. Life will be entitled to perform such audit no more than once per calendar year at its sole expense. All information acquired by said Auditor during the audit will be deemed Confidential Information under this
Agreement and the Auditor shall enter into a written confidentiality and non-use agreement under terms at least as restrictive as this Agreement prior to entering Licensee’s premises. Whilst at the Licensee’s premises, the Auditor will
abide by the Licensee’s rules and requirements for visitors and will not interfere with Licensee’s operations 
 2.5 No Implied
License. Nothing in this Agreement shall be construed as conferring explicitly or by implication, estoppel or otherwise any license, right or immunity under any rights that Life (and its successors, Affiliates and assigns, and successors,
Affiliates and assigns of each 

  
 Page 7 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 
of the foregoing) now owns or holds a license to, or acquires or obtains a license to in the future, other than the specifically identified Life Rights for use in connection with Licensee
Products. Furthermore, Licensee and its Authorized Affiliates have not provided and will not provide, and Life and its Affiliates have not received and will not receive, any consideration except that which is expressly provided herein for the
specific rights expressly granted herein. 
 3. Fees. 

3.1 Initial License Fee. As consideration for the rights granted to Licensee under this Agreement with respect to the First Licensee
Product, Licensee agrees to pay Life a one-time, non-refundable, non-creditable initial license fee of [***] USD ($[***]) (“Initial License Fee”) as follows: 

(a) the Parties agree that the amount of [***] USD ($[***]) previously paid by Licensee as a license fee under the Evaluation Agreement is
credited against this Initial License Fee due hereunder; and 
 (b) the remaining Initial License Fee in the amount of [***] USD ($[***]) is
due and payable within seven (7) days or the Effective Date. 
 3.2 Additional License Fee. For each Additional Licensee Product
that will be added to this Agreement, Licensee agrees to pay Life, in accordance with the schedule set forth in Section 2.2(c), the [***] additional license fee (“Additional License Fee”) as follows: 

(a) [***] USD ($[***]) for the first Additional Licensee Product; provided that such first Additional Licensee Product is added to this
Agreement until [***]; 
 (b) [***] USD ($[***]) for the second Additional Licensee Product; 

(c) [***] USD ($[***]) for the third Additional Licensee Product. 

In the event that Licensee pays [***], Licensee will have a fully paid-up license to use Life Cells in accordance with
the terms of the Agreement [***]. For the avoidance of doubt, obtaining such fully paid-up license shall not relieve Licensee of any payment of Change of Control fee as set forth in Section 8.1. 

For clarity, termination of this Agreement at any time after the Effective Date shall not relieve Licensee of any unfulfilled payment obligations of the fees
set forth herein. 
  

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and
(ii) would be competitively harmful if publicly disclosed. 

  
 Page 8 of 21 

 4. Payment. All payments due hereunder shall be payable in U.S. dollars and shall be
made by check or wire transfer to the appropriate account as follows: 
 Payment by check shall be made to: 

Thermo Fisher Scientific, Inc. 

Life Technologies Corporation 

5823 Newton Drive 
 Carlsbad, CA
92008 USA 
 Attention: Contract Management & Analytics (CMA) 

Payment by wire transfer shall be made to: 

[***] 
 Licensee shall be responsible for any and
all bank transfer charges associated with payments required to be made by it or its Authorized Affiliates under this Agreement 
 Any amount not paid by
Licensee when due will bear interest at an annual rate of [***] percent ([***]%) over the prime rate offered by Citibank N.A. on the date the payment is due until the due date the payment is made. The payment of such interest shall not prohibit Life
from exercising any other rights it may have as a consequence of the lateness of the payment. 
 5. Confidentiality; Press Release; Use of Life
Marks. 
 5.1 Confidential Information. The term “Confidential Information” in this Agreement means
all non-public or proprietary information disclosed by or on behalf of a Party or its Affiliates to the other Party pursuant to this Agreement, which may include ideas, inventions, discoveries, concepts, compounds, compositions, formulations,
formulas, practices, procedures, processes, methods, knowledge, know-how, trade secrets, technology, inventories, machines, techniques, development, designs, drawings, computer programs, skill, experience, documents, apparatus, results, clinical and
regulatory strategies, regulatory documentation, information and submissions pertaining to, or made in association with, filings with any Regulatory Authority, data, including pharmacological, toxicological and clinical data, analytical and quality
control data, manufacturing data and descriptions, patent and legal data, market data, financial data or descriptions, devices, assays, chemical formulations, specifications, material, product samples and other samples, physical, chemical and
biological materials and compounds, and the like, in whatever form or medium, and whether or not designated or marked “confidential” or “proprietary.” Confidential Information shall include the terms and conditions of this
Agreement. 
 5.2 Exclusions. Notwithstanding any other provision of this Agreement, Confidential Information shall not include any
item of information that the receiving party demonstrates: 
 (i) became generally available to the public other than as a result of
disclosure by the receiving party or its Affiliates; 
 (ii) was available to the receiving party and its Affiliates on a non-confidential basis prior to the disclosure to the receiving party by the disclosing party; 

 

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and
(ii) would be competitively harmful if publicly disclosed. 

  
 Page 9 of 21 

 (iii) became available to the receiving party or its Affiliates on a non-confidential basis
from a source other than the disclosing party; provided that, such source is not bound by an obligation of confidentiality to the disclosing party; or 

(iv) was independently developed by the receiving party without use of the Confidential Information as evidenced by written records. 

5.3 Non-Use and Confidentiality. The Parties shall maintain the Confidential Information in strict confidence and the Parties shall use
Confidential Information only in accordance with the terms and conditions of this Agreement. Each Party shall: 
 (i) limit its
dissemination of Confidential Information to only those employees and agents of such Party, Life’s Affiliates or Authorized Affiliates, who require such Confidential Information in order to exercise the rights of each Party, Life’s
Affiliates or Authorized Affiliates under this Agreement and such employees and agents shall be subject to obligations of confidentiality at least as restrictive as those specified herein; and 

(ii) not disclose, without the prior written consent of the other Party, Confidential Information to any Third Party other than to (a)
an Authorized Affiliate or Service Provider to the extent required for the purposes of this Agreement, (b) to a Regulatory Authority in connection with Regulatory Filings, or (c) to any Governmental Authority in accordance with
Laws. In the event that the receiving party or anyone to whom it transmits the Confidential Information pursuant to this Agreement becomes legally required to disclose any such Confidential Information, the receiving party shall provide the
disclosing party with prompt notice of such required disclosure so that the disclosing party may seek a protective order or other appropriate remedy and/or waive compliance with the provisions of this Agreement. In the event that such protective
order or other remedy is not obtained, the receiving party shall furnish only that portion of the Confidential Information which is legally required to be furnished in the written opinion of the receiving party’s counsel. The burdens of non-use
and confidentiality under this Agreement will continue until terminated by mutual agreement between the Parties hereto. 
 5.4 Press
Release. Neither Party will make any public press release or similar publicity announcement or disclosure that includes the other Party’s names, logos, trademarks or service marks, or the physical likeness or names of its employees or
investigators or other symbols of the other Party without the other Party’s prior written consent. 
 5.5 Limited Use of Life
Marks. Licensee shall not, at any time, employ any of the trade names, trademarks, trade dress, slogans, designs, or the like of Life or its Affiliates for any advertising, promotional, or other purposes without prior written permission to do so
from Life; provided, however, that Licensee may disclose the existence of this Agreement and the name of Life and its Affiliates to Licensee’s Authorized Affiliates, Service Providers and Third Parties, and to Regulatory
Authorities in connection with Regulatory Filings and in accordance with the requirements of any Governmental Authorities (subject to Section 5.3 above). 

  
 Page 10 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 6. Reservation of Rights. This Agreement shall not limit the rights of Life or its
Affiliates in any way regarding Life Rights. It is specifically understood that as between the Parties to this Agreement, Life reserves the right for itself or its Affiliates to exercise its rights in its intellectual property, and to license,
sublicense, assign or otherwise transfer such rights to others for any purpose whatsoever, under any terms, in its sole discretion, including terms and conditions that are substantially similar to or different from those in this Agreement. For
purposes of clarification, Life may provide Third Parties with draft contracts that are substantially similar to this Agreement and may additionally provide cell line documentation package, including the CLDP, to Third Parties at its sole
discretion. 
 This Agreement shall also not limit the rights of Licensee or its Authorized Affiliates to license their own intellectual property rights to
any Third Party. For clarity, in order for any Third Party to use Life Cells or any Life intellectual property rights thereto (including Life Rights) for commercial purposes (including without limitation
pre-IND commercial research), except as set forth in 2.1(c), such a Third Party must obtain a separate license from Life for consideration and on terms and conditions to be determined by Life, and it is a
material condition of this Agreement that Licensee inform its clients, potential licensees and other Third Parties interested in such rights of this requirement in writing with a copy of each such notification to Life. 

7. Term and Termination. 
 7.1
Term. This Agreement is effective as of the Effective Date, and will continue in perpetuity unless earlier terminated in accordance with this Section 7 (the “Term”). 

7.2 Termination by Licensee. Licensee may terminate this Agreement without specification of any reason with thirty (30) days’
prior written notice to Life. Any such termination shall become effective at the end of the thirty (30) day notice period. 
 7.3
Termination by Life. 
 (i) Upon a material breach or default of a material term under this Agreement by Licensee or an Authorized
Affiliate of Licensee, including without limitation a failure to pay fees owed as specified in this Agreement, this Agreement may be terminated by Life upon sixty (60) days prior written notice to Licensee (the “Cure Period”),
unless Licensee has cured any such material breach prior to the expiration of such Cure Period. 
 (ii) In the event that (a) Licensee
notifies Life, or (b) Life becomes independently aware, that any of Licensee’s Authorized Affiliates or a particular Service Provider is using Life Cells and/or CLDP other than as permitted under this Agreement (a “Non-Compliant Entity”), the rights conveyed by Licensee or its Authorized Affiliates to such Non-Compliant Entity under this Agreement may be terminated by Life upon
sixty (60) days’ written notice to Licensee, unless during said period the Non-Compliant Entity cures the non-compliant activities, and Licensee provides clear
written evidence of such cure to Life. 
 (iii) Life shall have the right to terminate this Agreement immediately at any time upon written
notice to Licensee in the event that continued performance under the Agreement may violate any Laws and such violation of Laws cannot be avoided by an amendment of the Agreement. Life shall communicate with Licensee regarding the circumstances
giving rise to such termination and shall use commercially reasonable efforts to provide Licensee with advance notice of such termination. Prior to terminating the Agreement as set forth herein, Life shall use commercially reasonable efforts to
mitigate the potential violation of any Laws. 

  
 Page 11 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 Termination by Life in compliance with this Section 7.3 shall not, in any event, constitute a breach of
this Agreement 
 7.4 Effect of Termination. 

(a) Upon the effective date of termination of this Agreement, all rights and licenses granted to Licensee and its Authorized Affiliates by Life
hereunder, including any rights extended by Licensee and/or its Authorized Affiliates to Service Providers, or Distributors shall automatically and immediately terminate and Licensee shall immediately stop, and shall cause (if applicable) its
Authorized Affiliates, Service Providers, and Distributors to immediately stop, exercising the license rights granted to Licensee in Section 2.1 of this Agreement. 

(b) Licensee shall, as soon as practicable, but in any event, within sixty (60) days following the effective date of termination of this
Agreement cause its Authorized Affiliates and Service Providers, to return to Licensee or destroy all Life Cells in such Authorized Affiliates’ and/or Service Providers’ possession, with certification of such return or destruction in
writing to Licensee (with a copy of such certification provided to Life upon request). 
 (c) Within thirty (30) days following the
effective date of termination of this Agreement, to the extent not otherwise required by law, Licensee will return to Life or destroy all copies of the CLDP and information provided therein which are in Licensee’s possession, and shall certify
such return or destruction in writing to Life. 
 (d) Upon termination for any reason of rights conveyed by Licensee or its Authorized
Affiliates to any Authorized Affiliate or Service Provider, under this Agreement, which termination does not include termination of the licenses granted to Licensee hereunder, Licensee shall, within thirty (30) days following the effective date
of such termination, cause the terminated Authorized Affiliate or Service Provider to return to Licensee or destroy all Life Cells in such Authorized Affiliate’s or Service Provider’s, possession and to certify such return or destruction
in writing to Licensee (with a copy of such certification provided to Life upon request). 
 (e) All rights and obligations of the Parties
set forth herein that expressly or by their nature survive the expiration, assignment or termination of this Agreement shall continue in full force and effect subsequent to, and notwithstanding the termination of this Agreement until they are
satisfied or by their nature expire and shall bind the Parties and their legal representatives, successors, and permitted assigns, including, without limitation (i) Sections 3 and 4 (to the extent that payment obligations existing
before expiration or termination of this Agreement remain unmet upon expiration or termination of this Agreement); and (ii) Sections 1, 5, 6, 7.4, 8, 9.5, 9.6, 9.7, 10, 11 and 12. 

8. Assignment/Transferability. 

8.1 Assignment by Licensee. This Agreement is personal to Licensee and neither this Agreement nor any right or obligation hereunder may
be assigned or otherwise transferred (whether voluntarily, by operation of law or otherwise, including, without limitation Licensee’s Change of Control) without the prior express written consent of Life, which shall not be unreasonably
withheld, Life’s consent may be subject to additional consideration. Notwithstanding the foregoing, Licensee may assign this Agreement once in connection with a Change of Control transaction without first obtaining such consent, subject to the
payment of a one-time, non-refundable, non-creditable Change of Control fee of [***] USD ($[***]) for all Licensee Products then in existence, corresponding to the
rights granted in Section 2.1(a) of the 

 

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and
(ii) would be competitively harmful if publicly disclosed. 

  
 Page 12 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 
Agreement, by the acquiring entity or assignee. Such payment shall be made within thirty (30) days of the Change of Control by the acquiring entity or assignee. In addition to the Change of
Control fee, the assignee is also required to pay any unpaid fees, as set forth in Section 3. For the avoidance of doubt, following the initial assignment as set forth above, Licensee, or Licensee’s successor in interest shall not
be permitted to assign or otherwise transfer the rights granted by Life in this Agreement without Life’s prior written consent. 
 8.2
Assignment by Life. Life may assign all or any part of its rights and obligations under this Agreement at any time without the consent of Licensee or its Authorized Affiliates or (if applicable) any successor or permitted transferee of
Licensee to whom this Agreement may have been assigned pursuant to Section 8.1. Licensee or (if applicable) any successor or permitted transferee agrees to execute such further acknowledgments or other instruments as Life may reasonably request
in connection with such assignment 
 8.3 Binding Effect. Any permitted assignment of this Agreement shall be binding on the assignee.
Any purported assignment or other transfer of this Agreement other than as expressly set forth in Section 2.1 or this Section 8 shall be null and void. 

9. Warranties and Representations; Acknowledgements; Limitation of Liability. 

9.1 By Life. Life represents and warrants that, as of the Effective Date, it has the full right and authority to enter into this
Agreement and to grant to Licensee the rights granted in Section 2 of this Agreement. For the avoidance of doubt, Life Cells were provided “as is” solely for Licensee to generate derivative products. Except as provided in this
Section 9.1, Life makes no representations or warranties concerning the Life Cells. 
 9.2 By Licensee. 

(a) Licensee represents, warrants and covenants to Life that: 

(i) Licensee has the full right and authority to enter into this Agreement; 

(ii) the use of Life Cells by Licensee, its Authorized Affiliates and Service Providers prior to the Effective Date has been in compliance
with the Evaluation Agreement; 
 (iii) Licensee has complied with and shall comply with and require its Authorized Affiliates and Service
Providers to comply with all (i) Laws (including, current Good Manufacturing Practices (cGMP)); (ii) requirements of Regulatory Authorities, and will obtain all applicable Regulatory Authorizations in connection with the
exercise of the rights granted to Licensee by Life hereunder. Licensee will issue, where appropriate, all necessary labelling and/or warnings related to human materials with respect to use of Life Cells and Licensee Products; 

  
 Page 13 of 21 

 (iv) Licensee and its Authorized Affiliates will conduct all additional tests to ensure the
safety, potency and purity of Licensee Products, including the testing of the Life Cells, any derivatives thereof, and any products, including Licensee Products that Licensee or its Authorized Affiliates offers for sale or sells or services that
Licensee or its Authorized Affiliates performs that are manufactured using, derivatives of, or ever came in contact with the Life Cells, for viral and/or bacterial contamination or other adventitious agents, and that it will remove any such
contamination or adventitious agent from any additional processes, materials, or products that Licensee may create using or that came in contact with Life Cells; 

(v) Licensee will not resell Life Cells; 

(vi) Licensee is solely responsible for determining the suitability of the Life Cells purchased from Life for use by Licensee; 

(vii) Licensee and its Authorized Affiliates, as applicable, will be responsible for obtaining any required Third Party intellectual property
rights with respect to Licensee’s and its Authorized Affiliates’ (a) use of Life Cells or Life Rights and (b) commercialization of Licensee Products, and Licensee acknowledges that any such Third Party rights are
not herein conferred by Life to Licensee by implication, estoppel, or otherwise; 
 (viii) Licensee shall not sell or cause to be sold, use
or cause to be used Licensee Products in any manner requiring Regulatory Authorization until it is finally obtained; and 
 (ix) Licensee
will comply with all applicable anticorruption and antibribery laws and will not knowingly take any action that would cause Life or any of its Affiliates to be in violation of such laws. As part of such compliance, Licensee represents that it shall
not offer or make any improper payments of money or anything of value to a non-U.S. Government Official in connection with this Agreement. Licensee shall not offer or make improper payments to a Third Party
knowing, or suspecting, that the Third Party will give the payment, or a portion of it, to a Government Official. 
 (b) Licensee
acknowledges and covenants that: 
 (i) Life Cells were originally sold by Life and its Affiliates for research use only and are expressly
not qualified for commercial, therapeutic or biotherapeutic purposes by Life or its Affiliates. Licensee assumes all responsibility and liability associated with Licensee’s use of Life Cells for human use; 

(ii) Life Cells have not been tested by or for Life for safety or efficacy or any other purpose, unless expressly stated in the CLDP or in
Life’s catalogues or on the label or other documentation accompanying the Life Cells at the time the Life Cells were sold to Licensee; 

(iii) there are gaps in the cell One history of Life Cells prior to the receipt of the original variants of the Life Cells by Life or its
Affiliates. Licensee agrees to assume all responsibility for addressing those gaps as may be requested by Regulatory Authority; 

  
 Page 14 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 (iv) Life developed Life Cells and provided Life Cells to Licensee without expectation that
Life Cells would be used in humans; and 
 (v) nothing in the Agreement shall be construed as conferring the right to use in advertising,
publicity or otherwise any trademarks or any contraction, abbreviation, simulation or adaptation thereof, of Life, except as expressly set forth herein. 

9.3 Mutual. Each Party represents and warrants to the other Party that (i) such Party is a company or corporation duly
organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized; (ii) such Party has the legal power and authority to execute, deliver and perform this Agreement; (iii) the
execution, delivery and performance by such Party of this Agreement has been duly authorized by all necessary corporate action; (iv) this Agreement constitutes the legal, valid and binding obligation of such Party, enforceable against
such Party in accordance with its terms; and (v) the execution, delivery and performance of this Agreement will not cause or result in a violation of any law, of such Party’s charter documents, or of any contract by which such Party
is bound. 
 9.4 Anti-Boycott. Notwithstanding any other provision of this Agreement, neither Licensee nor Life shall be required to
take or refrain from taking any action impermissible or penalized under the laws of the United States or any applicable foreign jurisdiction, including without limitation the anti-boycott laws administered by the U.S. Commerce and Treasury
Departments. 
 9.5 Disclaimer of Other Warranties. EXCEPT AS EXPRESSLY SET FORTH HEREIN, NEITHER LIFE NOR ANY OF ITS AFFILIATES MAKES
ANY WARRANTIES, EXPRESS OR IMPLIED OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE MANUFACTURE, USE, IMPORT OR SALE OF LIFE CELLS OR LICENSEE PRODUCTS OR THE USE OF CLDP WILL BE FREE FROM INFRINGEMENT OF ANY PATENT OR OTHER
INTELLECTUAL OR PROPRIETARY RIGHTS OF A THIRD PARTY. LIFE AND ITS AFFILIATES EXPRESSLY DISCLAIM ANY AND ALL WARRANTIES THAT THE USE OF LIFE CELLS, INCLUDING WITHOUT LIMITATION, THE USE OF LIFE CELLS IN THE MANUFACTURE OF LICENSEE PRODUCTS OR
COMPONENTS THEREOF, THE USE OF THE LIFE RIGHTS OR CLDP, OR THE USE OR TRANSFER OF SUCH LICENSEE PRODUCTS OR COMPONENTS THEREOF BY OR TO ANY AUTHORIZED AFFILIATE OR THIRD PARTY (INCLUDING A SERVICE PROVIDER), AND/OR ANY RESULTS OBTAINED BY USING SUCH
LIFE CELLS, LIFE RIGHTS, CLDP OR LICENSEE PRODUCTS OR COMPONENTS THEREOF, ARE, OR WILL BE, FREE FROM INFRINGEMENT OF ANY PATENT OR OTHER INTELLECTUAL OR PROPRIETARY RIGHTS OF THIRD PARTIES; AND THIS ALLOCATION OF RISK BETWEEN THE PARTIES IS
REFLECTED IN THE TERMS OF THE AGREEMENT AND IS AN ESSENTIAL ELEMENT OF THE BARGAIN BETWEEN THE PARTIES. 
 NEITHER LIFE NOR ANY OF ITS AFFILIATES MAKES ANY
WARRANTIES, EXPRESS OR IMPLIED, AS TO THE SUITABILITY OF THE LIFE CELLS FOR HUMAN USE OR COMMERCIALIZATION. 
 9.6 Indirect Damages.
NEITHER LIFE NOR ITS AFFILIATES SHALL BE LIABLE HEREUNDER TO LICENSEE, ITS AUTHORIZED AFFILIATES OR ANY OTHER PERSON OR ENTITY FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR OTHER INDIRECT DAMAGES (INCLUDING, BUT NOT LIMITED TO, LOSS OF
PROFITS OR LOSS OF USE DAMAGES) ARISING FROM THE MANUFACTURE OR USE OF LIFE CELLS OR LICENSEE PRODUCTS, OR THE USE OF THE LIFE RIGHTS OR CLDP, OR IN CONNECTION WITH THE PERFORMANCE OF THIS AGREEMENT, EVEN IF LIFE AND/OR ITS AFFILIATES HAVE BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSSES. 

  
 Page 15 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 9.7 Limitation of Liability. UNDER NO CIRCUMSTANCES SHALL THE TOTAL LIABILITY OF LIFE
AND ITS AFFILIATES, ARISING OUT OF OR RELATED TO THIS AGREEMENT INCLUDING, REGARDLESS OF THE FORUM AND REGARDLESS OF WHETHER ANY ACTION OR CLAIM IS BASED ON CONTRACT, TORT, OR ANY OTHER LEGAL THEORY, EXCEED THE TOTAL AMOUNT PAID BY LICENSEE
COLLECTIVELY TO LIFE AND ITS AFFILIATES HEREUNDER (DETERMINED AS OF THE DATE OF ANY FINAL JUDGMENT IN SUCH ACTION). 
 10. Export
Regulations. Licensee on behalf of itself and its Authorized Affiliates hereby agrees to comply with all applicable U.S. export laws administered by the FDA and U.S. export control and economic sanctions laws, regulations, and orders,
including without limitation those regulations maintained by the U.S. Treasury Department’s Office of Foreign Assets Control and the U.S. Commerce Department’s Bureau of Industry and Security Without limiting the foregoing, Licensee
covenants and agrees that neither it nor its Authorized Affiliates shall, directly or indirectly, sell, export, re-export, transfer, divert, or otherwise release or dispose of any equipment, product,
commodities, services, software, samples, materials, information, technical data, or technology received under this Agreement to or through any individual, entity, or destination, or for use prohibited by the laws or regulations of the U.S. or any
other applicable jurisdiction without having obtained prior authorization from the competent Governmental Authorities as required by all such laws and regulations. Licensee’s or any of its Authorized Affiliates’ breach of this provision
shall constitute cause for immediate termination of this Agreement. Licensee agrees to indemnify and hold harmless Life and its Affiliates for Licensee’s or any of its Authorized Affiliates’
non-compliance with these controls in connection with a breach of this provision. 
 11. Indemnity;
Insurance. 
 11.1 Indemnification by Licensee. Licensee shall defend, indemnify and hold Life, Life’s Affiliates, and
its and their respective officers, directors, employees and agents (the “Life Indemnitees”), harmless from and against all liability, damages, expenses (including reasonable attorneys’ and expert witness fees and expenses),
recoveries and losses resulting from any death, personal injury, illness or property damage (collectively, “Losses”) resulting from any claims (including any claims for infringement or misappropriation of intellectual property),
demands, actions, suits or proceedings (collectively, “Claims”) brought by a Third Party to the extent that such Claims arise out of, are based on, or result from (i) the replication or use of Life Cells by Licensee, its
Authorized Affiliates or Service Providers (ii) the use of Life Rights or CLDP by Licensee, its Authorized Affiliates or Service Providers; (iii) breach by Licensee or any of its Authorized Affiliates or Service Providers of
any representation, warranty or covenant made by Licensee in this Agreement or (iv) any use, sale, or import of Licensee Products, including but not limited to, use or reliance upon such Licensee Products or Life Rights, by Licensee, its
Authorized Affiliates, Service Providers and/or its or their Distributors or customers. 
 11.2 Indemnification Procedures. Life
Indemnitees shall give written notice to Licensee in a reasonably timely manner after learning of such Claim. Life Indemnitees shall provide Licensee with reasonable assistance, at Licensee’s expense, in connection with the defense of the Claim
for which indemnity is being sought. Life Indemnitees may participate in and monitor such defense with counsel of its own choosing at its sole expense; provided, however, that Licensee shall have the right to assume and conduct the
defense of the Claim with counsel of its 

  
 Page 16 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 
choice. Licensee shall not settle any Claim without the prior written consent of the Life Indemnitees, not to be unreasonably withheld or delayed, unless the settlement involves only the payment
of money. Life Indemnitees shall not settle any Claim without the prior written consent of Licensee. If Licensee does not assume and conduct the defense of the Claim as provided above, (i) Life Indemnitees may defend against, and consent to the
entry of any judgment or enter into any settlement with respect to, the Claim in any manner the Life Indemnitees may deem reasonably appropriate (and Life Indemnitees need not consult with, or obtain any consent from, Licensee in connection
therewith); and (ii) Licensee will remain responsible to indemnify the Life Indemnitees as provided in this Section 11. 

11.3 Insurance. Licensee will maintain the following insurance policies: 

(a) R&D Insurance. $[***] per occurrence, as of the Effective Date of this Agreement and until the date on which an IND with respect
to a Licensee Product is submitted to the FDA or a foreign equivalent. 
 (b) Clinical Trials Insurance. From the first day Licensee
commences clinical trials using materials manufactured using Life Cells (“Licensee’s Clinical Trial(s)”) and for at least five (5) years of consistent coverage (tail coverage for claims-made policy) after
termination of this Agreement, Licensee will maintain in effect Clinical Trial Insurance Coverage with limits and policy terms required by local Laws in the territories where the Licensee’s Clinical Trials are taking place and not less than:

 (i) [***] US dollars ($[***]) per occurrence upon commencement of clinical trial in human volunteers or patients, which shall be deemed
commenced when the first volunteer or patient in such study has received the initial dose of a Licensee Product (“Phase I Clinical Trial”); and 

(ii) [***] U.S. dollars ($[***]) per occurrence upon commencement of any Licensee’s Clinical Trials beyond Phase I Clinical Trial. 

(c) Insurance upon commercialization. Prior to or upon the grant of a Regulatory Authorization for the First Commercial Sale, Licensee
will maintain commercial general liability and product liability insurance, covering therapeutic products and Licensee’s obligations under the terms of this Agreement, including its indemnification obligations and costs for defense, for any
claims arising from bodily injury and property damage regarding the use of Life Cells with limits not less than [***] dollars ($[***]) per occurrence. This insurance policy will be maintained until the later of: (i) the expiration of any
applicable statute of limitations, (ii) [***] following termination of this Agreement, or (iii) [***] following the last sale of Licensee Products. The insurance policies, or certificates issued to Licensee evidencing such
insurance shall: 
 (i) Name as additional insured each of Life and its Affiliates; 

(ii) Be primary and non-contributing with, and not in excess of, any other insurance available to
Life; 
  

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and
(ii) would be competitively harmful if publicly disclosed. 

  
 Page 17 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 (iii) Have reasonable and customary deductible amounts compared to other similar companies
in the biotechnology and biopharmaceutical industry; and 
 (iv) Be issued by responsible insurance earners licensed to do business in the
state in which the project is located, and with a rating of not less than A-, as rated in the most currently available “Best’s Insurance Guide”. 

Licensee will also maintain locally admitted commercial general liability and/or other clinical trial coverage and product liability insurance, covering
therapeutic products and Licensee’s obligations under the terms of this Agreement, in any other territories where (i) Licensee operates, (ii) Licensee’s Clinical Trials are taking place, or (iii) Licensee Products are
manufactured, commercialized, or used, as required by applicable Laws. Such insurance policies shall name as additional insured each of Life and its Affiliates, if such additional insured language is customary in these territories. 

Certificates of insurance evidencing the coverage as required by this Section 11.3 will be delivered to Life by Licensee upon request. Licensee will
notify Life if the insurance policy is cancelled, suspended, non-renewed, terminated, or materially altered, within thirty (30) days from such change. 

It is solely Licensee’s responsibility to ensure it maintains the appropriate insurance and level of coverage as required herein, and to notify Life
immediately in the event a non-conformity. In the event of a failure or refusal by Licensee carry and maintain levels of insurance required herein or remedy any
non-conformity, Life, in addition to all other rights and remedies available to Life, will be entitled to treat such failure or refusal as a material breach of the Agreement. 

12. General. 
 12.1 Entire
Agreement. This Agreement constitutes the entire Agreement between Life and Licensee as to the subject matter hereof, and all prior negotiations, representations, agreements and understandings (including the Evaluation Agreement) are merged
into, extinguished by and completely expressed by this Agreement This Agreement may be modified or amended only by a writing executed by authorized officers of both of the Parties. 

12.2 Notices. Any notice required or permitted to be given by this Agreement shall be given in writing in English by postpaid, first
class, registered or certified mail, or by courier or facsimile, property addressed to the other Party at the respective address as follows: 
  

					
	        	 	If to Life:	  	If to Licensee:
		 	Thermo Fisher Scientific, Inc.	  	BridgeBio Services, Inc.
		 	Life Technologies Corporation	  	Gene Therapy
		 	5823 Newton Drive	  	421 Kipling St
		 	Carlsbad, CA 92008 U.S.A.	  	Palo Alto, CA 94301
		 	Attn: Contract Management and & Analytics	  	Attn: Finance and Operations
		 	(CMA)	  	[***]
		 	[***]	  	

  

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and
(ii) would be competitively harmful if publicly disclosed. 

  
 Page 18 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 Either Party may change its address by providing notice to the other Party. Unless otherwise specified
herein, any notice given in accordance with the foregoing shall be deemed given within four (4) Business Days after the day of mailing, or one (1) Business Day after the date of delivery to the courier, as the case may be. 

12.3 Governing Law. This Agreement shall be interpreted and enforced in accordance with laws of the State of California in the United
States of America, without regard to its conflicts of laws rules, provided, that those matters pertaining to the validity or enforceability of patent rights shall be interpreted and enforced in accordance with the laws of the territory in which such
patent rights exist. The parties expressly agree that the application of the United Nations Convention on Contracts for the International Sale of Goods (1980) is specifically excluded and shall NOT apply to this Agreement. 

12.4 Compliance with Laws. Each Party agrees to comply with Laws in exercising its rights and performing its obligations under the
Agreement. Nothing in this Agreement shall be construed so as to require the commission of any act contrary to law, and wherever there is any conflict between any provision of this Agreement or concerning the legal right of the Parties to enter into
this Agreement and any statute, law, ordinance or treaty, the latter shall prevail, but in such event the affected provisions of this Agreement shall be curtailed and limited only to the extent necessary to bring it within the applicable legal
requirements. 
 12.5 Injunctive Relief. Notwithstanding anything herein seemingly to the contrary, either Party may seek injunctive
relief from a court of competent jurisdiction to prevent or limit damage to that Party’s Confidential Information or otherwise preserve the status quo pending the proceeding. 

12.6 Relationship of Parties. The relationship of the Parties is that of independent contractors, and nothing herein shall be construed
as establishing one Party or its Affiliates as the agent, legal representative, joint venturer, partner, employee, or servant of the other Party or its Affiliates. Except as set forth herein, neither Party shall have any right, power or authority to
assume, create or incur any expense, liability or obligation, express or implied, on behalf of the other Party or its Affiliates. No Party shall hold itself out as being the agent, legal representative, joint venturer, partner, employee, or servant
of the other Party or its Affiliates or as having authority to represent or act for the other Party or its Affiliates in any capacity whatsoever, except as authorized herein. 

12.7 Force Majeure. If the performance of this Agreement or any obligation hereunder (except for the payment of money) is prevented,
restricted or interfered with by reason of fire or other casualty or accident, strikes or labor disputes, inability to procure raw materials, power or supplies, war, invasion, civil commotion or other violence, compliance with any order of any
governmental authorities or any other act or conditions whatsoever beyond the reasonable control of either Party hereto, the Party so affected upon giving a prompt notice to the other Party shall be excused from such performance to the extent of
such prevention, restriction or interference; provided, however, that the Party so affected shall use commercially reasonable efforts to avoid or remove such causes of non-performance and shall continue
performance hereunder with the utmost dispatch whenever such causes are removed, to the extent commercially reasonable. 
 12.8 Waiver,
Modifications and Amendments. The failure of any Party to insist on the performance of any obligation hereunder shall not be deemed to be a waiver of such obligation. Waiver of any breach of any provision hereof shall not be deemed a waiver of
any other breach of such provision or any other provision on such occasion or any succeeding occasion. No waiver, modification, release or amendment of any obligation under or provision of this Agreement shall be valid or effective unless in writing
and signed by the Parties. 

  
 Page 19 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 12.9 Headings. Headings used herein are for descriptive purposes only and shall not
control or alter the meaning of this Agreement as set forth in the text. 
 12.10 Severability. Should one or more of the provisions
contained in this Agreement be held invalid, illegal or unenforceable by a court or tribunal with jurisdiction to do so, then the validity, legality and enforceability of the remaining provisions contained herein shall not be affected or impaired
thereby, unless the absence of the invalidated provision(s) adversely affect the Parties’ substantive rights. In such instance, the Parties shall use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid,
legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement. 
 12.11 Counterparts. This
Agreement may be signed in one or more counterparts, all of which together shall constitute one and the same Agreement, binding on the Parties as if such Parties had signed the same document. 

IN WITNESS WHEREOF, the Parties intending to be legally bound have caused this Agreement to be executed by their respective duly authorized representatives as
of the Effective Date. 
  

									
	For Life:	  		  	For Licensee:
			
	Life Technologies Corporation	  	            	  	BridgeBio Services, Inc.
					
	By:	 	 /s/ Deborah Day Barbara
	  		  	By:	  	 /s/ Eric David

	(signature)	  		  	(signature)
					
	Name:	 	 Deborah Day Barbara
	  		  	Name:	  	 Eric David

	(please print)	  		  	(please print)
					
	Title	 	 Sr Director, Therapeutic Licensing
	  		  	Title:	  	 Chief Executive Officer

					
	Date:	 	 November 27, 2018
	  		  	Date:	  	 November 26, 2018

  
 Page 20 of 21 

			
	EXECUTION COPY	  	CONFIDENTIAL

  

 EXHIBIT A 

AUTHORIZED AFFILIATES 
 Authorized
Affiliates: 
 (1) Adrenas Therapeutics Inc., a Delaware corporation having its principal place of business at 421 Kipling Street, Palo Alto, California
94301, USA 
 (2) Aspa Therapeutics Inc., a Delaware corporation having its principal place of business at 421 Kipling Street, Palo Alto, California 94301,
USA 

  
 Page 21 of 21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]